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Abstract 
Background:  In the United States alone, Type 2 Diabetes is the 7th leading cause of death, with 
Alzheimer’s Disease ahead as the 6th leading cause of mortality.  While specific mechanisms 
have yet to be recognized by mainstream medicine, the term Type 3 Diabetes has been adopted 
to describe diabetes of the brain.  Overarching commonalities amongst each disease include (a) 
oxidative stress, (b) inflammation, (c) mitochondrial dysfunction, and (d) neuroendocrine 
abnormalities.  Collectively, these factors have been found to directly contribute to pro-death 
genes, impaired energy metabolism, and cerebral hypoperfusion.  Yet, Type 2 Diabetes remains 
one of the most adjustable risk factors for the development of Alzheimer’s Disease.  This 
dissertation explores the available literature on increasing the awareness of Type 3 Diabetes in 
terms of present and future implications.   
Methods:  The review highlighted the following topics: (a) Alzheimer’s disease, (b) Types 1 and 
2 diabetes, (c) insulin resistance and cognitive decline, (d) Type 3 diabetes (e) ApoE(4) genetic 
perturbations, (f) prevention and lifestyle support for Alzheimer’s disease, (g) prevention and 
lifestyle support for diabetes, (h) social and economic consequences of Alzheimer’s disease, (I) 
social and economic consequences of diabetes. 
Results:  While AD is a complex disorder, there is a plethora of irrefutable research that 
supports viewing it as Type 3 Diabetes.  Increasing patient education of Type 3 Diabetes and 
focusing on prevention strategies would decrease disease burden, increase quality of life and at 
the same time, save trillions of dollars in healthcare spending.   
Conclusions:  Since there is no pharmaceutical cure for AD, increasing awareness of Type 3 
Diabetes has the potential to provide patients with sustainable, integrative therapies, allowing 
them to become invested in their health choices.  This will also promote individual 
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accountability and a sense of conscientiousness in taking back one’s own health through lifestyle 
choices while reducing unnecessary suffering for patients, family members and society. 
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Increasing Awareness of Type 3 Diabetes: Present and Future Implications 
Chapter 1 
Introduction 
 Background.  Nowadays, many people are familiar with Type 1 or Type 2 Diabetes 
Mellitus, however, there is another form of diabetes that has just recently been identified, known 
as Type 3 Diabetes.  This lesser-known type manifests as insulin resistance within the brain and 
has major potential to impact neurocognition and contribute to the etiology of Alzheimer’s 
Disease [AD].  Type 3 Diabetes is more commonly denoted as diabetes of the brain, putting 
people at an augmented risk of developing AD within their lifetime.  Alzheimer’s Disease has 
already been identified as the sixth leading cause of death in the United States, and the fifth 
leading cause of mortality in people 65 and older (Kandimalla, Thirumala & Reddy, 2017).  
Unfortunately, diabetes is following right behind AD as the 7th leading cause of mortality and 
has been projected to affect almost 400 million people by the year 2030 (Centers for Disease 
Control & Prevention [CDC], 2017).   At the same time, type 2 diabetes has remained one of the 
most adjustable risk factors for the development of Alzheimer’s Disease (Pugazhenthi, Qin & 
Reddy, 2017).     
 Both diseases have been recognized to have multifactorial interactions involving both the 
environment and to a lesser degree, genetics.  Yet, insulin insensitivity has been linked to 
memory deficits, cognitive decline, and many of the characteristic symptoms that have been 
displayed in Alzheimer’s Disease (Kandimalla, Thirumala & Reddy, 2017).   Evidence has also 
concluded that while most cases of AD are “sporadic and do not exhibit clear familial or genetic 
clustering” there are multiple overlapping neurodegenerative mechanisms in both diabetes and 
AD, leading to the discovery of type 3 diabetes (Pugazhenthi, Qin & Reddy, 2017).  Specific 
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overarching mechanisms that have been identified include, (a) oxidative stress, (b) inflammation, 
(c) mitochondrial dysfunction, and (d) neuroendocrine abnormalities (Steen et al., 2005).  
Collectively, these factors have been found to directly contribute to “pro-death genes and 
signaling pathways, impaired energy metabolism, and cerebral hypoperfusion” (Steen et al., 
2005).   
How Are Populations Affected? 
 Economic & Social Consequences. In the world today, 44 million people have been 
diagnosed with AD, with an estimated global healthcare burden of $605 billion (Song, Bischoff, 
Song, Uyemura & Yamaguchi, 2017).  At the same time, diabetes diagnoses have increased 
worldwide from “108 million in 1980 to 422 million in 2014” and have costed Americans $300 
billion in 2012 alone (Song, Bischoff, Song, Uyemura & Yamaguchi, 2017).  Unfortunately, AD 
has been projected to affect 106 million people by 2050 (Hyman, 2016).  These numbers have 
been particularly crippling in the face of AD because we have yet to develop “efficient disease-
modifying therapies” or low-cost diagnostic measures, (Chen & Zhong, 2013).  There is no 
question that AD is a “pressing issue in today’s society” that has the potential to affect every 
family (Chen & Zhong, 2013).  If lifespan continues to increase due to pharmacological and 
scientific advancements in medical technology, current projections have estimated that close to 
100% of people worldwide have the potential of developing cognitive decline in the form of 
Alzheimer’s Disease at some point in their existence (Chen & Zhong, 2013).  This information 
not only identifies the gravity of our current chronic disease crisis regarding Type 3 Diabetes, but 
it also pinpoints the indispensable and immediate need for preventative measures.  
 Newly emerging research has highlighted the importance of diagnosing prediabetes, or 
impaired glucose tolerance with a hemoglobin A1C level on the threshold of elevation, to 
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prevent progression to Type 2 Diabetes (Hyman, 2016).  This research also indicates that 
prediabetics have an augmented risk of developing pre-dementia or mild cognitive impairment 
[MCI] (Hyman, 2016).  Diabetics have characteristically exhibited a four-fold increased risk for 
developing AD (Hyman, 2016).  At the same time, prediabetics are a rapidly rising subgroup in 
the development of pre-dementia symptoms including sporadic forgetfulness, memory loss, and 
deficiencies in performing everyday tasks (Hyman, 2016).  Unfortunately, today, it is very 
commonplace for families to utilize outside care for once thriving members of society, 
contributing to both the economic burden of disease, but also psychological stress from all sides.  
The most debilitating aspects have traditionally involved loved ones who fail to recognize family 
members or the need to sell all possessions to pay for care.  Afflicted individuals perceived as 
“slipping away” have a significantly reduced quality of life while families are forced to drain 
household resources.  Other major consequences include gradual loss of autonomy coupled with 
no home, very few personal possessions and a healthcare system that has yet to provide any 
effective clinical treatment.  The emotional anguish and stress on family members forced to 
make these difficult decisions while watching a loved one suffer has the potential to contribute to 
even more detrimental health outcomes in the process.  
Immediate Need for Improvement.  AD has been identified as the most common form 
of dementia, affecting nearly 15 million Americans by the year 2050 (Song, Bischoff, Song, 
Uyemura & Yamaguchi, 2017).  At the same time, Type 2 Diabetes has been projected to reach 
epidemic numbers within the next decade (CDC, 2017).  The identification of preventative 
strategies has the capacity to alleviate a significant amount of death, unnecessary suffering and 
financial burden for all of humankind (Song, Bischoff, Song, Uyemura & Yamaguchi, 2017).  
According to Song et al. (2017), unhealthy lifestyle choices that (a) perpetuate the inflammatory 
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cascade (b) induce insulin resistance, and (c) provoke oxidative stress have been identified as 
“the most significant risk factors for AD” (p. 42).  It has also been established that while genetic 
predispositions in ApoE(4) allele variations may play a role in the etiology of AD, this 
traditionally has accounted for “5-7% of all cases worldwide” leaving the other 93 to 95% 
attributable to the interplay between multifactorial environmental complexities as epigenetic 
mediators (Wang & Ding, 2008).   
On the same note, it has been well ascertained in the literature that Type 2 Diabetes is 
largely preventable (CDC, 2017).  While the specific mechanisms between AD and all forms of 
diabetes remain convoluted and unclear, increasing the awareness of AD as a third form of 
diabetes has the potential to provide a plethora of proactive and therapeutic strategies to current 
patients.  These include prevention through weight control, healthy lifestyle choices that can 
reduce AGE formation and anti-inflammatory nutritional support to thwart the oxidative cascade 
both systemically and within the brain (Wang & Ding, 2008).  This realization also identifies the 
need for patient education in prediabetic phases as a proactive approach against chronic disease 
etiology (Wang & Ding, 2008). According to Hyman (2016), in order to properly target such a 
multifaceted disease, all contributing factors must be addressed when developing patient protocol 
and these include (a) addressing hormonal imbalances, (b) reducing inflammation through diet 
and lifestyle, and, (c) preventing disease progression through proper neuronal support.   
AD has been associated with conspicuous diminutions in both insulin and IGF-1 mRNA 
expression and “downregulation of the corresponding receptors” within the brain (Steen et al., 
2005).  This suggests that a different or more multifaceted disease process within the CNS may 
provoke these outcomes, hence the term “Type 3 Diabetes” (Steen et al., 2005).  Increasing 
evidence has also identified oxidative stress, mainly due to excessive formation of free radicals, 
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as a main contributor to the “pathogenesis of neuron degeneration” (Markesbery & Carney, 
1999).  Type 3 Diabetes has been recognized in conjunction with a diagnosis of AD because of 
the communal mechanisms among Type 1, Type 2 Diabetes Mellitus and AD, particularly due to 
the breakdown in the “action of glucose absorption in the neurons for energy production” 
(Kandimalla, Thirumala & Reddy, 2017).  These interconnected physiological mechanisms 
include inflammation as a hallmark feature, mainly neuroinflammation in relation to AD and 
systemic inflammation characteristic of diabetes (Silzer & Phillips, 2018).  Interestingly enough, 
increased oxidative stress measured through lipid peroxidation products has been identified as a 
potential measurement tool in identifying patient risk factor for AD development (Silzer & 
Phillips, 2018).  This, along with mitochondrial distress, coupled with the natural effects of aging 
have all been hypothesized to precipitate hyperphosphorylation of tau protein and neurofibrillary 
tangles also deemed as classic signs of AD in postmortem research (Silzer & Phillips, 2018).  
Therefore, treating AD as a disease of diabetes-like complexities that manifests in the brain may 
have the potential to reveal powerful therapies in combating this debilitating and progressive 
condition (Silzer & Phillips, 2018).   
Since Type 2 Diabetes is preventable and reversible, this information has the potential to 
open the door for proactive and preemptive approaches that target the overlapping mechanisms 
described in this dissertation (Kandimalla, Thirumala & Reddy, 2017).  Therefore, improvements 
in targeting the causative inflammatory mechanisms of AD will be crucial in thwarting the 
progression of the disease.  One such improvement can begin in the medical community with 
recognizing that cognitive decline and progressive brain damage can begin with prediabetes and 
chronic insulin resistance (Hyman, 2016).  Along with increasing awareness for the term, Type 3 
Diabetes, recognizing that the brain and the body are “one elegant and symbiotic unit” can help 
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reveal the detrimental and shared impacts that poor lifestyle choices can have on both the body 
and the brain (Hyman, 2016). It is also crucial to increase both patient and clinician education as 
proactive tools in developing sustainable and effective therapeutic interventions before 
neurological damage has time to progress (Malik et al., 2012).  
Key Terms 
 The following definitions are illustrated to ensure uniformity and understanding of these 
terms throughout the dissertation.   
Advanced glycation end products (AGEs): Also known as glycotoxins, which are a 
distinct group of highly oxidant compounds with pathogenic significance in chronic 
diseases, specifically diabetes (Uribarri et al., 2010).    
Alzheimer’s disease (AD): A degenerative brain disease named after Dr. Alois Alzheimer 
characteristic of irreversible, progressive memory loss. Abnormal deposits of proteins 
form amyloid plaques and tau tangles throughout the brain, resulting in premature 
neuronal death (National Institutes of Health [NIH], 2016).  
Diabesity: A term used to suggest a causal pathophysiological link between obesity and 
type 2 diabetes (Amen, 2015).   
Insulin resistance:  A condition characterized by the inability of the body to respond to 
and use the insulin it produces.  It is associated with hypertension and obesity (CDC, 
2014).   
Neurofibrillary tangles (NFTs): These insoluble, jumbled masses are made up of 
abnormal proteins and twisted fibers that are typically seen in postmortem AD diagnoses 
(Bright Focus Foundation, 2017).   
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Persistent Organic Pollutants (POPs): Long-lasting chemical toxins that are transported 
by wind and water that adversely affect human health and the environment (Kovner, 
2009). 
Receptor for advanced glycation end products (RAGEs): A prime member of the 
immunoglobulin family of molecules that has multiple ligands and has been identified to 
play a crucial role in chronic disease pathology including diabetes, cancer, heart disease 
and AD (Pugazhenthi & Reddy, 2017). 
Tau: Microtubule-associated proteins fostering the formation of characteristic 
neurofibrillary tangles and neuritis in Alzheimer’s disease (Steen et al., 2005).   
Type 1 Diabetes Mellitus: Also known as Juvenile diabetes or rapid onset.  A condition 
characterized by high blood glucose levels caused by lack of insulin production due to 
autoimmune targeting of the insulin-producing beta cells in the pancreas (CDC, 2014).  
Type 2 Diabetes Mellitus:  A condition characterized by high blood glucose levels caused 
by either a lack of insulin or the body’s inability to use insulin efficiently (CDC, 2014).  
Type 3 Diabetes Mellitus:  An emerging term describing Alzheimer’s disease as a form of 
diabetes that selectively implicates the brain and has molecular and biochemical features 
that overlap with both type 1 and type 2 diabetes mellitus (de la Monte & Wands, 2008).   
Research Rationale 
We currently live in an era classified as a healthcare crisis where wait times to see a 
primary care provider are at an all-time high.  There are major shortages in the healthcare 
workforce, and current practitioners are overworked and overstressed.  In fact, the typical time 
spent with a doctor lasts roughly 9 minutes, leaving very little time for patient insight, disease-
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specific education or even the answering of any pertinent questions (See Appendix A), (Gold, 
2014).   
The detrimental effects of quantity over quality regarding patient care has created a mechanical-
like reactive response to disease management through deferment-strategies that have typically 
hinged on disease recurrence or the development of severe disease (Hu, 2016).  Prevention and 
implementation of subsequent approaches have become subordinate, inferior concepts partly due 
to the overwhelming numbers of patients requiring care.  However, this area has greatly 
contributed to the relevance and potential of increasing awareness of Type 3 Diabetes as research 
has been built on the premise of providing patients with the tools to take back their own health 
(Hu, 2016).   
Presently, there is no greater need than to provide some sustainable, proactive approaches 
to a problem projected to afflict most people within their lifetime, especially since aging has 
been identified as the number one risk factor for AD (Leszek et al., 2017).  By the year 2030, 
12% of the population will be considered elderly (Leszek et al., 2017).  At the same time, Type 2 
Diabetes has become a worldwide emergency that continues to decimate both the healthcare 
system in general and the economy of every nation (Leszek et al., 2017).  Due to the lack of 
effective strategies in AD management, research has focused on specific molecular foundations 
that contribute to AD pathology, which has revealed the potential of AD as a brain-specific, third 
type of diabetes (De Felice et al., 2014).  Increasing awareness of Type 3 Diabetes has the 
possibility of providing effective therapeutic strategies to millions of people suffering from AD 
or any range of cognitive decline.  This is hugely relevant because modern medicine has few 
treatments for AD, none without major side effects, and we have yet to identify any long-term 
treatments successful in preventing disease progression.   
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As chronic diseases like diabetes and AD continue to rise to epidemic proportions, 
preventative measures remain vital players in the fight against the current reactive healthcare 
cycle.  According to Castelnuovo et al. (2014), nutrition persists as a fundamentally influential 
factor when it comes to disease etiology, prevalence, incidence and prognosis.  Raising 
awareness of Type 3 Diabetes as a disease with largely modifiable risk factors can empower an 
individual with the knowledge and the tools to forecast his or her own individual health based on 
proactive information, screenings, and lifestyle education (Hu, 2016).  This empowered patient 
will then make lasting and sustainable changes to achieve health instead of becoming a casualty 
of a system that leads to predisposed healthcare destinies like AD with no effective protocol 
(Bashshur et al., 2014).   
Purpose of the Research 
AD diagnoses are expected to upsurge exponentially within the next few years and will 
continue stalling an already overly taxed healthcare system.  With this in mind, increasing the 
awareness of a biochemical link between AD and type 2 diabetes can have serious health 
implications for current and future generations.  Moreover, emerging evidence links prevention 
as a key factor in reducing disease prevalence by fostering patient education, empowerment and 
improving access for underserved populations (Bashshur et al., 2014).  This just may be what the 
doctor ordered in reducing disease pervasiveness, adopting preventative strategies and increasing 
awareness of Type 3 Diabetes, which is the main purpose of this research. 
 Examining this evidence is an objective of this paper, along with identifying the potential 
of multitargeted Type 3 Diabetes therapies as the foundation for effective disease management.  
Pharmaceutical interventions will be explored that convalesce insulin sensitivity, thanks to their 
success in the treatment, reversal and prevention of Type 2 Diabetes (De Felice et al., 2014).  
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This literature review will also include the possibilities of non-pharmaceutical approaches like 
diet, exercise, and anti-inflammatory lifestyle choices. Based on the current evidence identifying 
Type 2 Diabetes as largely preventable and reversible, a major goal of this research is to discover 
the implications this information has going forward for Type 3 Diabetics. 
 Other research questions that will be explored in this dissertation include: 
1. What are the current and future implications of increasing the awareness of the term Type 
3 Diabetes? 
2. What are some recommendations for proactive therapeutic approaches to Type 3 
Diabetes? 
3. What are the overlapping neurodegenerative mechanisms that explain the term Type 3 
Diabetes? 
4. Why should Type 3 Diabetes be more widely accepted? 
5. How are ApoE(4) genetic carriers specifically affected regarding faulty insulin signaling? 
6. Should ApoE(4) screening be incorporated for Type 2 Diabetics and possibly 
prediabetics? 
7. If Type 2 Diabetes is preventable and reversible, what promise does this have for Type 3 
Diabetes and the stages of cognitive decline? 
8. What does the research reveal about AD patients without Type 2 Diabetes? 
9. How can future research take advantage of the term Type 3 Diabetes in developing 
effective strategies for the progressing stages of AD? 
This research intends to demonstrate the powerful effects of recognizing AD as Type 3 
Diabetes and to present the current evidence-based literature.  The hope is for the medical 
community to accept this term so that going forward, effective therapies can be adopted for every 
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stage of the disease. While providing the current evidence in the field of Type 3 Diabetes, this 
dissertation will also deliver recommendations and possible solutions to the problem in order to 
identify the importance of viewing the disease as a manifestation of multifaceted mechanisms.  
This information will allow the birth of treatment options that have the potential to be developed.  
At the same time, it will also provide a deeper understanding of disease pathology so that 
proactive approaches can reduce pain, suffering and overall disease burden.  Most importantly, a 
final purpose is to provide evidence to current patients who have been waiting anxiously for 
effective clinical interventions, and to deliver hope for relief with the potential for improvements 
in quality of life.   
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Chapter 2 
Review of Literature 
Alzheimer’s Disease and Insulin Resistance  
This literature review addresses Alzheimer’s Disease, the well-established links between 
neurodegenerative disease and Type 2 Diabetes, and the potential for increasing awareness of 
Type 3 Diabetes.  Due to the overlapping yet distinct pathological features among diabetes, 
insulin resistance and cognitive decline, multitargeted drug therapies along with lifestyle 
interventions are also explored (Kandimalla, Thirumala & Reddy, 2017, p. 1078).  Extensive 
amounts of current literature have recognized the increased risk factor for the development of 
Alzheimer’s Disease in people with Type 2 Diabetes and correlations have suggested roughly 
half or more of all diabetics will develop some form of cognitive decline (Heerema, 2018).  
Both diseases have been recognized to have multifactorial interactions involving both the 
environment and to a lesser degree, genetics.  Yet, insulin insensitivity has been linked to 
memory deficits, cognitive decline, and many of the characteristic symptoms that have been 
displayed in Alzheimer’s Disease (Kandimalla, Thirumala & Reddy, 2017).   Evidence has also 
concluded that while most cases of AD are “sporadic and do not exhibit clear familial or genetic 
clustering” there are multiple overlapping neurodegenerative mechanisms in both diabetes and 
AD, leading to the discovery of type 3 diabetes (Pugazhenthi, Qin & Reddy, 2017).  While 
associations are complex and severity is dependent upon (a) the extent of inflammation (b) 
insulin resistance, and (c) other subjective environmental factors, there have been patients that 
develop Alzheimer’s disease without prior diabetic diagnoses (de la Monte & Wands, 2008, p. 
1105).   This may be because thousands of people have gone undiagnosed with diabetes for 
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many years, or in some people, the effects of insulin resistance may remain relatively 
sequestered to the neural tissues of the brain (de la Monte & Wands, 2008, p. 1105).   
Alzheimer’s disease can be diagnosed with greater than 85% accuracy via postmortem 
identification of neurofibrillary tangles, amyloid precursor proteins and plaque deposits in 
specific regions (de la Monte & Wands, 2008).  This has led to the discovery of diabetes-like 
malfunctions in the brains of AD patients that may embody a “brain-specific form of diabetes 
mellitus” or Type 3 Diabetes (de la Monte & Wands, 2008).  Mounting postmortem evidence has 
seemed to classify AD as a selective form of diabetes involving the brain with the potential for 
“molecular and biochemical features” that intersect with Type 1 and Type 2 Diabetes (de la 
Monte & Wands, 2008).  These features have been shown to diminish normal neuronal pathways 
over decades and “contribute to cognitive decline” while compromising quality of life 
(Pugazhenthi & Reddy, 2017).  It has been established that weakened dynamics within 
metabolism have positive associations with “AD-related pathology in humans” (De Felice et al., 
2014).  The metabolic parameters most implicated have included hyperglycemia, 
hyperinsulinemia and more specifically, faulty pathways within insulin signaling that has the 
potential to leave the brain starved for energy (De Felice et al., 2014).  The exact connections 
between this interplay have yet to be elucidated but have been hypothesized to lie within the 
hippocampus, which serves as the memory center of the brain (De Felice et al., 2014).  From 
what we know about healthy cognitive functioning, the hippocampus can generate roughly 700 
new hippocampal stem cells daily (Amen, 2015).  This is important to consider regarding AD 
and Type 3 diabetes because through environmental considerations, we have the power to either 
grow or shrink neuronal tissues that directly influence memory and cognition (Amen, 2015).  
Neurogenesis is no longer a hypothetical notion but a proven phenomenon under the proper 
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conditions, which means that it is possible for people to regrow brain cells even in AD-related 
pathology (Amen, 2015).  At the same time, certain conditions foster the continuation of 
premature cell death and further cognitive decline.   
Why Type 3 Diabetes Should Be Widely Accepted 
Diabetes Distinctions. Type 1 Diabetes is associated with a complex pathology in which 
autoimmune reactions target pancreatic beta-cells, severely diminishing or halting insulin 
production altogether (Boles, Kandimalla & Reddy, 2017).  This results in insulin resistance and 
the need for lifelong support in the form of exogenous insulin (Boles, Kandimalla & Reddy, 
2017).  Patients diagnosed with Type 1 Diabetes have characteristically shown increased 
glutamic acid decarboxylase [GAD] activity, which functions as an “autoantigen” in the brain 
and pancreas (Boles, Kandimalla & Reddy, 2017).  Heightened GAD action has also been known 
to perpetuate the autoimmune response through inflammatory responses within the brain (Boles, 
Kandimalla & Reddy, 2017).  Individuals who have been diagnosed with Type 2 Diabetes have 
“blood sugar levels that are higher than normal” along with insulin resistance and deficiency and 
an augmented risk factor for the development of other chronic diseases, most notably, AD 
(Boles, Kandimalla & Reddy, 2017).  Persistently high glucose levels have been shown to take a 
major toll on every organ system by reducing normal signaling and starving healthy cells from 
receiving the appropriate fuel for survival (Boles, Kandimalla & Reddy, 2017).  Type 2 Diabetes 
has been identified as a major 21st century problem with detrimental implications for the heart 
and vascular system, the kidneys, the liver, and most recently, the brain.   
Type 3 Diabetes is a form that distinctly affects neurocognition within the brain.  Like 
Type 2, it has been linked to “metabolic derangements of carbohydrates, lipids, proteins” 
coupled with cognitive decline in the presence of excessive oxidative stress from insulin 
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resistance and faulty mitochondrial signaling within the brain (Mittal & Katare, 2016).  Type 3 
Diabetes has also been identified in the phosphorylation of tau proteins through increased 
glycogen synthase kinase signaling leading to mitochondrial malfunction and significant 
decreases in energy production (Mittal & Katare, 2016).  Consequences include premature 
neuronal death and the cognitive degeneration exhibited in AD (Mittal & Katare, 2016).   
Diagnosis of Type 3 Diabetes.  Both Type 1 and Type 2 Diabetes can be definitively 
diagnosed by measuring fasting glucose and glycated hemoglobin to detect hyperglycemia 
(Amen, 2015).  However, multiple indicators coupled with clinical observations must be utilized 
to ultimately diagnose Type 3 Diabetes, mainly because it is related to insulin resistance within 
the brain.  Metabolic markers that can point to a potential Type 3 Diabetes diagnosis include 
utilizing many of the same markers that confirm a Type 2 Diabetes diagnosis, like fasting 
glucose and glycated hemoglobin to examine blood sugar levels (Hyman, 2016).  Symptoms and 
clinical observations that can be used in identifying Type 3 Diabetes include prolonged memory 
loss or decline (beyond mere forgetfulness), an assessment of independent function, memory 
assessment in planning, judgement, and key thinking skills (Amen, 2015).  Brain imaging and/or 
neuropsychological testing can also shed light on structural deficits within the brain itself that 
can be characteristic of Type 3 Diabetes (Amen, 2015).  Serum C-peptide as a measure of insulin 
production may be one of the best indicators for insulin resistance, yet it is often overlooked by 
mainstream medicine (Zanardini et al., 2018).  According to Zanardini et al. (2018), high levels 
of C-peptide along with high fasting insulin levels are associated with an increased risk of 
neurodegenerative disease.   
The downstream and detrimental effects of untreated diabetes on the vascular system 
have been well documented in the literature.  Yet, many times, researchers leave the vascular 
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system of the brain out of the equation when examining systemic outcomes (Amen, 2015).  At 
the same time, the vessels of the brain may be even more fragile and reactive to hyperglycemia 
and insulin resistance than the vessels within the extremities (Amen, 2015).  Because of this, 
brain imaging tests like MRIs or CT scans can provide a picture of the vasculature of the brain 
(Amen, 2015).  Cerebrospinal fluid samples can also reveal inflammatory peptides circulating 
within the central nervous system that precipitate AD (Amen, 2015).  People with symptoms of 
Type 2 Diabetes who have symptoms of poor memory, declining cognition, and unexplainable 
brain fog can be educated on the connections between brain health and optimal blood sugar 
levels in managing their diabetes and at the same time, slow the progression of AD (Amen, 
2015).   
According to a study from the University of Pennsylvania Perelman School of Medicine, 
insulin resistance may be the single most important contributor to cognitive decline “above and 
beyond other known causes of AD” (2012).  This information makes diagnosing Type 3 Diabetes 
much more feasible particularly in people who have already been diagnosed with Type 2 
Diabetes.  At the same time, this study found evidence of insulin resistance in non-diabetics 
“hence the absence of hyperglycemia outside the brain” (Arnold & Talbot, 2012).  This may 
illustrate a brain-specific phenomenon in glucose uptake for cellular “growth, survival, 
remodeling and functioning” (Arnold & Talbot, 2012).  Evidence identifying the need for 
normalization or re-sensitization of brain cells to insulin may hold the key to “slow down, 
prevent or perhaps even improve cognitive decline” (Arnold & Talbot, 2012).  This information 
combined with the utilization of other inflammatory biomarkers like C-reactive protein, can shed 
light on the extent of the inflammatory cascade in relation to the neurological microenvironment 
(Amen, 2015).   This is all vital information in the diagnosis of Type 3 Diabetes in people who 
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may not have systemic blood sugar problems, which may explain the need for genetic screening 
to identify potential ApoE(4) carriers who demonstrate severe malfunctions in insulin signaling 
(Arnold & Talbot, 2012).  Genetic predisposition is expanded upon further in the literature 
review, along with Type 3 Diabetes in non-diabetics.   
Pharmaceutical connections.  Alzheimer’s Disease and diabetes have also been linked 
from the perspective of research in the pharmaceutical industry.  Recent discoveries have 
revealed that diabetes medications from the thiazolidinedione class “have intrinsic 
neuroprotective and anti-inflammatory effects” along with the capacity to reduce brain-related 
insulin resistance (De Matos, De Macedo & Rauter, 2017).  While metformin has been 
traditionally associated with cognitive decline and stress-induced oxidative damage in Type 2 
Diabetics, current research in mice has challenged these prior findings (See Appendix B) (De 
Matos, De Macedo & Rauter, 2017).  De Matos, De Macedo and Rauter (2017) have found that 
metformin has the potential to “exert neuroprotective effects, being able to prevent scopolamine-
induced cognitive impairment” and brain damage in rats.  Though the need for larger clinical 
trials in humans is required before drawing fixed conclusions, intranasal insulin has shown 
promise in vivo (De Matos, De Macedo & Rauter, 2017).  Specific research shows perception 
improvements in ApoE(4) carriers “with mild cognitive impairment or early AD stage” (De 
Matos, De Macedo & Rauter, 2017).  Galantamine, which has been approved by the FDA for AD 
treatment, has also been indicated as a “potential antidiabetic agent” since it has shown potential 
to improve “insulin signaling pathways, lipid metabolism, and beta cell function” with 
multitarget potential (See Table 1, Appendix C), (de Matos, de Macedo & Rauter, 2017).   
At the same time, metformin drugs come with a slew of nutritional depletions and side 
effects like abdominal pain, anxiety, painful urination and general discomfort (de Matos, de 
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Macedo & Rauter, 2017).  Berberine, a natural alterative to metformin, has natural glucose-
lowering properties and research has even identified it as a possible anti-diabetic agent (Cai, 
Wang & Yang, 2016).  According to Cai, Wang and Yang, berberine exhibits beta-amyloid 
clearing by lowering the “activity of beta-site amyloid precursor protein cleaving enzymes” 
(2016).  Berberine can easily pass through the blood brain barrier, target and clear beta-amyloid 
plaques and exhibit neuroprotective effects (Cai, Wang & Yang, 2016).  This prevents 
neurodegeneration, particularly in the hippocampus, which is extremely susceptible to cellular 
impairment (Cai, Wang & Yang, 2016).   
While Alzheimer’s Disease was originally discovered in 1906 by Dr. Aloysius 
Alzheimer, very few pharmaceutical advancements have been made in prevention or disease 
treatment protocol (Stein, Schettler, Rohrer & Valenti, n.d.).  At the same time, we have 
expanded our knowledge of brain neurochemistry particularly within the last decade.  We now 
know that brain scans of people with chronically high levels of blood glucose show detrimental 
effects within various structures of the brain, predominantly the hippocampus, or the memory 
center of the brain (Kerti et al., 2013).  Deficits in both short-term and long-term recall have been 
established as hallmark symptoms of cognitive decline, as identified by Dr. Alzheimer in his 
initial protocol for suspected patients (Stein, Schettler, Rohrer & Valenti, n.d.).  This 
phenomenon has even been identified in people without a formal Type 2 Diabetes diagnosis and 
has suggested that the hippocampus is particularly susceptible to instabilities in glucose 
regulation (Kerti et al., 2013).   
Overlapping Neurodegenerative Mechanisms 
Oxidative Stress and AGEs.  Alzheimer’s Disease represents the largest field where 
oxidative stress has been extensively examined (See Appendix D), (de Matos, de Macedo & 
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Rauter, 2017).  According to Markesbery and Carney (1999), the accumulation of free radical 
damage within the brain has been implicated for some time in premature neuronal death and 
plays a major role in AD pathogenesis (p. 133).  Postmortem examinations have collectively 
revealed “increases in lipid peroxidation, a decline in polyunsaturated fatty acids (PUFA)” along 
with augmented oxidation of proteins (Markesbery & Carney, 1999).  All of the individual 
mechanisms collectively lead to a discernable deterioration of enzymatic functioning 
(Markesbery & Carney, 1999).  This is showcased through various functional biomarkers 
measuring DNA oxidation, most specifically, hyperoxidation of 8-hydroxy-2’-deoxyguanosine 
(Markesbery & Carney, 1999).  The study utilized organic acids testing (OAT) for this marker, 
which has the ability to provide information about biochemical imbalances within the body by 
measuring urinary metabolic byproducts (Markesbery & Carney, 1999).     
Steen, et al. (2005), has suggested that oxidative damage reduces the ability of the brain 
to properly utilize glucose, mainly through weakened signaling in insulin and insulin-like growth 
factor types I and II within the central nervous system [CNS] (p. 64).  Since neuronal death 
perpetuates the loss of the ability of the CNS to produce appropriate growth factors, insulin 
expression is greatly reduced, potentially favoring the development of tau mRNA and amyloid 
precursor proteins as compensatory mechanisms (Steen et al., 2005).  This oxidative cascade has 
elicited characteristics similar to diabetes (Steen et al., 2005) However, in many patients who 
never had diabetes, the phenomenon remained sequestered to the brain, distinct from both Type 1 
and Type 2 Diabetes (Steen et al., 2005).   
Hyperglycemia and dyslipidemia have been identified as hallmark features of diabetes 
and in many cases, precede AD (Silzer & Phillips, 2018, p. 17).  At the same time, accumulation 
of advanced glycation end products [AGEs] has been detected in diabetic animals and in humans 
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through postmortem analyses (Pugazhenthi & Reddy, 2017, p. 1039).  AGEs have been 
established as glycotoxins or oxidized compounds created excessively through the Maillard 
reaction (Uribarri et al., 2010).  They are also produced as a result of normal metabolic processes 
and their accumulation has been associated with pathologic inflammatory effects in diabetes 
(Uribarri et al., 2010).  In a state of chronic inflammation where most antioxidant stores have 
been exhausted, AGEs accumulate and perpetuate the inflammatory cycle by inducing the 
formation of fibrillary tangles and amyloid plaque found in AD (Pugazhenthi & Reddy, 2017).   
According to a systematic review by Pugazhenthi and Reddy (2017), AGE formation 
provokes an upsurge in the inflammatory receptor known as RAGE (receptor for advanced 
glycation end products).  RAGE has been identified as a “putative receptor for excessive tau 
phosphorylation” which decreases the brain’s capacity to clear Aβ proteins (p. 1039).  According 
to Silzer and Phillips (2018), oxidative stress “via measurement of specific lipid peroxidation 
products” has been detected in patients with notable cognitive decline prior to recognition of the 
“classic indicators of AD” (p. 17).  These metabolic end products have emerged as important 
biomarkers for early detection, even in dementia patients without diagnosed diabetes (Silzer & 
Phillips, 2018).  AGEs have also been shown to enhance vascular cell adhesion in “endothelial 
cells and subsequent inflammation” while aggravating arteriosclerotic conditions (Shinohara & 
Sato, 2017).  Of particular interest is this exact phenomenon in “acceleration of vascular injury” 
within the brain in hypertensive patients since hypertension is another diagnosis of which half of 
all diabetics experience (Shinohara & Sato, 2017).   
While prior research has undoubtedly uncovered the toxic nature of high levels of AGEs 
in both the serum and cerebrospinal fluid, very little research has investigated specific links 
between AGEs and AD (Leszek et al., 2017).  With this being said, AGEs have been detected 
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within neurofibrillary tangles, which have been concomitant in the pathogenesis of AD (Leszek 
et al., 2017).  At the same time, it has been well founded that Type 2 Diabetics have extremely 
high levels of AGEs in systemic circulation based on serum markers, leading to further 
correlation between AD, AGEs and Type 2 Diabetes (Leszek et al., 2017).  This has provided 
additional evidence in connecting the dots between each phenomenon, which may hold the 
promise for exposing the complexities in each etiology while revealing concurrent 
manifestations.   
Mitochondrial Dysfunction.  The mitochondria have been established as the 
powerhouse of the cell, responsible for metabolism, cellular signaling, and apoptosis when 
damage occurs (Chornenkyy, Wang, Wei & Nelson, 2018).  For these reasons and as a central 
player in energy metabolism, mitochondrial dysfunction plays a crucial role in the pathogenesis 
of AD and diabetes (Chornenkyy et al., 2018).  According to Baloyannis (2006), “mitochondrial 
mass, size and copy number” have been shown to be decreased in the brains of AD patients.”  
However, the most fascinating evidence has revealed a reciprocal relationship between 
mitochondrial diversity and β-amyloid peptide deposits (See Appendix E), (Lee et al., 2018).  
This suggests a detrimental effect, mainly increased “mitochondrial membrane permeability” in 
the presence of β-amyloid deposits (Baloyannis, 2006).  Also indicated is the potential for a 
“self-propagating cycle with increasing β-amyloid peptide production” and deteriorating 
mitochondrial functionality (Baloyannis, 2006).   
In well-balanced neural cells, impaired mitochondria are distinctly recognized and 
degraded “via an autophagy pathway” known as mitophagy (Chornenkyy et al., 2018).  This 
process is triggered by standard signaling within and among cells as an innate quality control 
mechanism (Chornenkyy et al., 2018).  In the early stages of AD, mitophagy has been shown to 
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be upregulated which decreases clearance of autophagic substrates (Chornenkyy et al., 2018).  
Mitochondrial homeostasis is also disrupted, favoring the production of tau and β-amyloid 
deposition via compensatory pathways (Chornenkyy et al., 2018).  Mitochondrial dysfunction 
has been identified as a hallmark feature in both diabetes and Alzheimer’s etiology (Silzer & 
Phillips, 2018).  Instead of viewing these diseases as ‘copathologies’ this research shows the 
need to view mitochondrial abnormalities as a root cause.  With this being said, mitochondrial 
support may provide a therapeutic strategy for both AD and Type 2 Diabetes (Silzer & Phillips, 
2018).   
Inflammation.  Proinflammatory cytokines (through markers such as C-reactive protein 
and IL-6) have been identified in “CSF and β-amyloid plaques” of postmortem AD patients 
(Chornenkyy et al., 2018).  These markers are also amplified in diabetes diagnoses and have 
generally been associated with cognitive impairments (Chornenkyy et al., 2018).  
Proinflammatory particles have even been linked to “inducing a prothrombotic state” by 
triggering “vascular events leading to brain infarction,” hence their direct and detrimental 
influence on cognition (Marioni, Strachan, Reynolds, Lowe, Mitchell, & Fowkes, et al., 2010).  
Neuroinflammation has been identified as “a main contributor to the AD pathogenesis” and 
according to de Matos, de Macedo and Pilar Rauter (2017), underlying inflammation has been 
isolated as a culprit in amyloid plaque formation, extreme oxidative cycles, endothelial 
malfunction, enzymatic signaling along with possible genetic connections.  Certain individuals 
may be more genetically susceptible to higher inflammatory markers, like interleukin-6 (IL-6) 
due to single nucleotide polymorphisms (Feng et al., 2014).  Based on research from Feng et al. 
(2014), serum levels of IL-6 “were found to be significantly higher with genotypes containing 
the G allele in healthy subjects.”  This has suggested that there is a genetically predetermined 
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dissimilarity in the degree of IL-6 measurements in individuals and highlights the importance of 
genetic markers as potential inflammatory indicators (Feng et al., 2014).   
Pharmaceutical implementations including metformin have been criticized and linked to 
the possible perpetuation of cognitive decline (de Matos, de Macedo & Pilar Rauter, 2017).  This 
highlights the need for more research in disease prevention and anti-inflammatory strategies (de 
Matos, de Macedo & Pilar Rauter, 2017). Ferreira, Clarke, Bomfim and De Felice (2014) have 
identified the term “inflamm-aging” in the etiology of both AD and diabetes.  This underscores 
the immediate requirement for preventive strategies targeted at alleviating inflammatory 
mediators and thwarting the inflammatory cascade from a metabolic perspective. Increasing 
awareness of Type 3 Diabetes from a clinical perspective can support the proactive notion of 
preventative medicine through early screening and patient education.  Diagnostic measures for 
confirming Type 3 Diabetes are discussed on page 22 of the literature review.   
Diabesity.  In our modern society, roughly 40% of Americans are considered obese 
(CDC, 2017).  This statistic combined with the current diabetes epidemic has birthed the term 
diabesity, particularly considering recent findings of the reciprocal relationship between weight 
gain and brain size in humans (Amen, 2012).  According to the research, waist-to-hip ratio is 
inversely correlated with hippocampal size, which stands as the memory processing center of the 
brain (Amen, 2012).  At the same time, overweight people in the study had 4% less brain volume 
than healthy controls with a biological brain age eight years older than the patient’s 
chronological age (Amen, 2015).  When brain scans of obese subjects were compared to healthy 
controls, they revealed 8% less brain volume with biological brain ages that averaged nearly 16 
years older than the subjects’ chronological ages (Amen, 2015).  The connections lie within the 
prefrontal cortex which has shown decreased function along with hippocampal atrophy as weight 
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increases (Amen, 2015).  Of interest is the notion that fat on the body stores toxins and increases 
inflammatory cytokines.  Diabesity combined with genetic predisposition has the power to 
damage the entire vasculature, including blood vessels within the brain (Amen, 2015).  This 
leads to ongoing brain damage in the form of premature cell death and the exact inflammatory 
cascade showcased in AD (Amen, 2015).   
Neuroendocrine Abnormalities.  Nearly a century ago, Sir Harold Himsworth observed 
the declining relationship between “insulin resistance and central nervous system function” 
(Cholerton, Baker & Craft, 2011).  Insulin has since been dubbed the “master regulator of 
corporeal ageing in all known species” and has also been linked to systemic expression of 
ageing, specifically in the brain (Cholerton, Baker & Craft, 2011).  It is also well known that 
insulin works as a transport mechanism of the amino acids tryptophan and tyrosine in crossing 
the blood brain barrier (Cholerton, Baker & Craft, 2011).  These building blocks directly regulate 
the neurotransmitters serotonin and dopamine, which work together to regulate excitatory 
impulses within the brain.  Cognitive decline has been associated with diminished insulin 
efficiency either from deficient cellular response or “reduced insulin transport across the blood-
brain barrier (Cholerton, Baker & Craft, 2011).  Normally, insulin has the ability to cross the 
blood brain barrier through transcytosis in order to reach different regions throughout the brain 
(Ferrannini et al., 1999).  However, chronically high insulin production propagates excitatory 
impulses “to the sympathetic nuclei” while binding receptors that stimulate the systemic stress 
response through cortisol and prolactin release (Ferrannini et al., 1999).   
Based on original research from Steen et al. (2005), postmortem brain tissue in patients 
with diagnosed AD has demonstrated significant reductions in “insulin and IGF-1 receptor 
expression levels in AD frontal cortex, hippocampus and hypothalamus” (p. 75).  A majority of 
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the samples examined showed no significant observational changes to the cerebellum (Steen et 
al., 2005).  These changes have been investigated beyond the downstream manifestation of 
neuronal death, demonstrating the connection between impaired signaling and neurodegeneration 
(Steen et al., 2005).  This research has pointed to abnormalities at the receptor-level regarding 
insulin expression, “which may have future therapeutic implications” (Steen et al., 2005).   
It has also been well established that insulin or IGF-1 has the ability to upregulate or 
downregulate tau phosphorylation (Steen et al., 2005).  This is a precipitating factor in the 
accumulation of neurofibrillary tangles in the pathogenesis of AD (Steen et al., 2005).  While 
high peripheral insulin levels in relation to AD development have been established as a common 
risk factor for neurodegeneration, not every AD patient has been or will be diagnosed with 
diabetes (Steen et al., 2005).  However, “a clear relationship has been established between 
impaired insulin signaling and premature neuronal death, which reveals a selective disparity 
localized to the brain, which may indicate type 3 diabetes” (Steen et al., 2005).  Retrospective 
research has proposed that senile plaque formation is analogous among patients with both AD 
and diabetes as well as in patients with AD absent of diabetes (Shinoharo & Sato, 2017).   
Peripheral glucose metabolism has been a particular field of interest, specifically 
regarding impairments in CNS control of glucose levels in patients with AD (Ngandu et al., 
2015).  A large, randomized, controlled trial identifying lifestyle and dietary interventions in 
patients with dementia demonstrated “improvements in cognitive function” in at-risk populations 
(Ngandu et al., 2015).  These results directly reveal “bidirectional interactions” between AD and 
diabetes (Ngandu et al., 2015).  According to the Baltimore Longitudinal Study of Aging autopsy 
cohort investigation, glucose metabolism “is affected early in AD” and findings have revealed 
“neural insulin resistance” (An, Varma, Varma, Casanova, Dammer, Pletnikova et al., 2018).  
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The acuteness of AD pathology may hinge on GLUT3 levels.  For instance, the lower the levels, 
the more severe the AD symptoms (An et al., 2018).  Duran-Aniotz and Hetz (2016) found that 
“overexpression of GLUT-1” improves glucose metabolism and reduces AD-associated 
cognitive alterations.  This indicates the possible therapeutic effect of restoring normal glucose 
metabolism within the brains of AD patients.  While these findings were exhibited in drosophila 
species, more mammalian studies are needed to demonstrate connections.  At the same time, it is 
well established that the pathology of AD occurs decades before clinical onset.  Conclusions of 
this study identify the need to define specific mechanisms behind failure of glucose transporters 
within the brain and not just compensatory mechanisms like plaque formation or tau 
phosphorylation (Duran-Aniotz & Hetz, 2016).   
The notable downstream effects of chronic insulin resistance are of particular importance 
for current and prospective research.  Research continues to shed light on “the weakening of 
insulin transition by the blood brain barrier” and possibly, the facilitation and modulation of tau-
protein formation due to activation of insulin resistant reductions in phosphorylating kinase 
activity (Leszek et al., 2017).  The literature shows that insulin resistance itself leads to (a) 
mitochondrial abnormalities, (b) oxidative stress, (c) “reductions in synaptic plasticity in the 
hippocampus” (Leszek et al., 2017).  Research also shows that these effects are greatly 
exacerbated with the natural aging process coupled by a sedentary lifestyle and lack of proper 
nutrition (Leszek et al., 2017).  However, the positive aspect of this literature reveals that the 
problem can also be the solution in the form of anti-inflammatory lifestyle choices (See 
Appendix F), (de Matos, de Macedo & Pilar Rauter, 2017).  This information, combined with 
anti-diabetic therapy targeted to normalize insulin signaling within the central nervous system, 
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has the potential to reroute insulin resistant pathways and possibly foil AD pathogenesis (Leszek 
et al., 2017).   
ApoE(4) Genetic Carriers and Insulin Signaling 
Genetic Connections.  Both the vascular alterations exhibited in patients with Type 2 
Diabetes along with the inflammatory cascade characteristic of obesity have the potential to 
increase risk of dementia by nearly four-fold (Zhao et al., 2017).  At the same time, research in 
genetics has highlighted the role the ApoE(4) gene may play in defective insulin signaling (Zhao 
et al., 2017). According to Zhao et al. (2017), people who carry the ApoE(4) gene have 
accelerated impairments with insulin signaling, which has been linked to decreased neuronal 
functioning (See Appendix G).  Research has shown that in ApoE(4) carriers, insulin receptor 
signaling becomes trapped inside the neuron, specifically within the endosome, due to the 
production of the ApoE(4) protein (Zhao et al., 2017).  This deflects signaling by blocking 
receptors located on the surface of the neuron, stalling insulin utilization further (Zhao et al., 
2017).  As the process continues, the ApoE(4) protein continues to “clump,” advancing the 
detrimental cycle, resulting in cellular starvation and ultimately, apoptosis (Zhao et al., 2017).  
Research has shown that roughly 20% of the population has this genetically-rooted error in 
“insulin trafficking,” placing this population at an augmented risk for AD (Zhao et al., 2017).  
When coupled with Type 2 Diabetes and the natural aging process, genetic carriers may be 
subjected to the perfect storm of detrimental factors for brain health (Zhao et al., 2017).   
Current research has also linked amyloid-beta plaque production to potential genetic 
predisposition.  Yet, considering the findings from Zhao et al. (2017), “it is still unclear whether 
amyloid beta and ApoE(4) play synergistic or competing roles in disrupting insulin signaling.”   
At the same time, ApoE(4) has been found to have a much higher binding affinity to insulin 
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receptors, even in cases where amyloid-beta fails to be present (p. 124).  The presence of 
ApoE(4) alone has not been established as an independent risk factor for Type 2 Diabetes or for 
AD (Zhao et al., 2017).  However, the culmination of molecular mechanisms underlying genetic 
signaling, combined with the insulin resistance already present in Type 2 Diabetes have the 
capability to produce brain-specific insulin signaling abnormalities (Zhao et al., 2017). 
According to Johnson et al. (2017), mice carriers of the ApoE(4) gene have shown a “global 
metabolic shift toward increased lipid oxidation” as a compensatory mechanism to make up for 
“cerebral glucose hypometabolism.”  It has yet to be established, however, as to the origin of this 
occurrence.  The question of whether these metabolic shifts transpire primarily during oxidative 
phosphorylation, through glycolysis or “at the level of the blood brain barrier” still remain 
(Johnson et al., 2017).  Going forward, this may be further evidence that the mechanisms within 
the brain as a result of loss of insulin signaling have distinct regulatory pathways within the 
central nervous system (Johnson et al., 2017).  Increasing awareness of Type 3 Diabetes in the 
clinical realm may provide the exact culminating designation that can harness both improvement 
and treatment strategies of this multifaceted disease (Zhao et al., 2017).   
Genomic research has further identified the role that both epigenetics and metabolomics 
continue to play in discerning amongst risk factors for AD between carriers versus noncarriers of 
the ApoE(4) gene (Johnson et al., 2017).  Imaging reports have revealed signs of “brain 
hypometabolism in the same regions affected by AD” in carriers of the ApoE(4) gene in their 
early twenties (Johnson et al., 2017).  This further supports an augmented risk in allele carriers 
compared to noncarriers (Johnson et al., 2017).  Additionally, the presence of genetic alterations 
like ApoE(4) and amyloid beta plaques underscore the notion that increased carbohydrate intake 
has a significantly higher inflammatory effect in genetically predisposed individuals (Johnson et 
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al., 2017).  Epigenetic signaling has been established as having a crucial role in both the 
“functional impairments” and succeeding revitalization of healthy pathways, highlighting the 
importance of individualized dietary interventions as a “novel therapeutic target for AD and 
related dementias” (Johnson et al., 2017).  Research has also connected the ApoE(4) gene with 
other conditions like (a) vascular dementia, (b) mild cognitive impairment, (c) elevated LDL 
cholesterol, and (d) cardiovascular disease due to its role in macronutrient transportation (Stein, 
Schettler, Rohrer & Valenti, n.d.).  These correlations have further illustrated the inflammatory 
cycle that perpetuates in chronic disease and may hold major promise for utilizing proactive 
genetic screening for prevention (See Appendix H), (Stein, Schettler, Rohrer & Valenti, n.d.).    
Metabolomics.  Future research is also vital in emerging fields like genetics, epigenetics 
and metabolomics, which studies small molecules or metabolites of physiological pathways. The 
dynamic interplay of environmental factors and metabolism is vital for further understanding of 
signaling routes, suppression or promotion of repair mechanisms in carriers versus non carriers 
of implicated genes and biochemical individuality (Johnson et al., 2017).  Gene therapy “to 
deliver glucose transporters into the hippocampus and other areas affected in AD could emerge 
as attractive strategy” to stop cognitive damage and even reverse these alterations for AD 
patients (Duran-Aniotz & Hetz, 2016).  These types of individualized therapies have shown 
promise in vitro in restoring energy imbalances within the brain.  They may pave the way for 
mitochondrial support by “improving the buffering capacity of the cell against abnormal protein 
aggregation” which is critical for carriers of the ApoE(4) gene (Duran-Aniotz & Hetz, 2016).  It 
has been made abundantly clear that the “neuropathological cascade of AD” manifests its 
subtleties decades before clinical inception (Duran-Aniotz & Hetz, 2016).  Delineating the 
mechanism that facilitates the breakdown of energy transport may enhance patient protocol while 
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providing preventative strategies for such an incapacitating disease (Duran-Aniotz & Hetz, 
2016).   
Epigenetics.  We have only recently begun to understand the gene-environment 
interchange.  As a rule, the disease or health of every organ system has the potential to be 
influenced by various circumstances and environmental components (Stein, Schettler, Rohrer & 
Valenti, n.d.).  Traditionally, these circumstances have been apportioned into either genetic 
variances or environmental factors.  Yet, often, there is an intermingling amongst phenomenon, 
which has launched the field of epigenetics (Stein, Schettler, Rohrer & Valenti, n.d.).  In cases of 
ApoE(4) genetic carriers, observational research has identified Westernized lifestyle factors as a 
potential indicator in assessing individual disease risk for AD and diabetes (Stein, Schettler, 
Rohrer & Valenti, n.d.).  One such observational study has determined that (a) physical 
inactivity, (b) drinking alcohol, (c) smoking, and (d) consuming a Westernized diet as potent 
modifiers in determining dementia risk “particularly among genetically susceptible individuals” 
(Stein, Schettler, Rohrer & Valenti, n.d.).  Other evidence has been supportive in identifying the 
Westernized diet as a “key driver of ApoE(4)-associated risks” particularly when having been 
exposed to high levels of environmental chemicals (Stein, Schettler, Rohrer & Valenti, n.d.).  
The most common offenders include lead, aluminum, air pollution and persistent organic 
pollutants or POPs (Stein, Schettler, Rohrer & Valenti, n.d.).  The current evidence has 
accentuated the role that chronic inflammation plays in the etiology of both AD and Type 2 
Diabetes (Mushtaq et al., 2014).  Consequently, the manipulation of various “inflammatory 
pathways and the development of new treatments for both of these diseases” may effectively 
treat type 2 diabetes while delaying the onset of AD (Mushtaq et al., 2014).  Research has 
undoubtedly established the importance of adjusting environmental aspects in preventing “risks 
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associated with ApoE(4) and potentially a major portion of the Alzheimer’s/dementia burden” 
(Stein, Schettler, Rohrer & Valenti, n.d.).  However, future endeavors must expand on this by 
shedding light on individual vulnerability and dietary and environmental exposures in 
determining disease risk (See Appendix I), (Stein, Schettler, Rohrer & Valenti, n.d.)  
Implications of Increasing Awareness of Type 3 Diabetes 
Early Detection.  Chronic disease statistics both globally and domestically have revealed 
staggering increases in diagnoses (CDC, 2017).  Projections for medical costs “associated with 
treatment and hospital stays” due to complications are also skyrocketing (Boles, Kandimalla & 
Reddy, 2017).  This has identified the indispensable need for early detectable markers for 
prediabetics and the necessity for future AD research in teasing out the complexities among 
diabetes and cognitive decline (Boles, Kandimalla & Reddy, 2017).  Modifiable factors that may 
reduce diabetes have the probability of preventing AD, which starts with patient education 
regarding physical activity, diet, avoiding unnecessary inflammatory substances and having 
proactive clinical support regarding disease monitoring (Song, Bischoff, Song, Uvemura & 
Yamaguchi, 2017).  In the insightful words of Dr. Daniel Amen (2015), “we cannot change what 
we do not measure.”  Systemic biomarkers of inflammation can provide much needed insight 
into an individual’s biochemical makeup and potentially thwart disease if caught early (Amen, 
2015).   
Significance of Information Presented. The brain-specific alterations exhibited in post-
mortem AD research cannot be ignored, particularly regarding the “deterioration of the brain’s 
ability to use and metabolize glucose” (Heerema, 2018).  It also well noted in the literature that if 
a person is diagnosed with diabetes, their risk of developing AD doubles (Heerema, 2018).  Add 
obesity, genetic factors, and inflammatory conditions like high blood pressure and the risk is 
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further heightened (Heerema, 2018).  According to de la Monte and Wands (2008), 
“epidemiologic studies provide convincing evidence for a significant association between T2DM 
and AD” (p. 1103).  However, the degree of association is based on individual factors that 
directly influence underlying inflammation including (a) exposure to AGEs; (b) blood pressure; 
(c) patient age, and (d) BMI (de la Monte & Wands, 2008).  Significant associations between 
poor lifestyle choices, Type 2 Diabetes and AD have been established epidemiologically 
(Ferreira, Bomfim & De Felice, 2014).  However, the greatest associations have been made 
clinically as “mounting recent evidence indicates undeniable shared mechanisms of pathogenesis 
between metabolic disorders and AD” (Ferreira, Bomfim & De Felice, 2014).  Based on research 
from Steen et al. who first coined the term Type 3 Diabetes, “the neurodegeneration that occurs 
in sporadic AD is consistently associated with a number of histopathological, molecular and 
biochemical abnormalities” (2005, p. 63).  Further evidence has revealed that impaired insulin 
signaling plays a major role in AD pathogenesis, based on epidemiological findings (Steen et al., 
2005).  Based on a systematic review conducted by Leszek et al., (2017), cumulative evidence 
has evoked a strong correlation between AD and DM, birthing the term Type 3 Diabetes (p. 
1333).   
Research has also identified a strong association between brain-specific insulin resistance 
and cognitive decline, highlighting the need for new or current therapies to target insulin 
signaling (Steen et al., 2005).  This information is vital in pursuing “multi-modal” and effective 
treatments that “target distinct impairments at different levels within the insulin signaling 
cascades” in the brain (de la Monte et al., 2012).  This has the potential to relieve a significant 
burden of disease both nationally and worldwide as healthcare costs are projected to reach $4 
trillion by 2020 (Kandimalla, Thirumala & Reddy, 2017).   
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Effective Pharmaceuticals for AD 
Anti-Diabetic Agents.  Clinical trials exploring AD medications have notoriously fallen 
short, mainly because they have traditionally focused on the elimination of plaque deposits or tau 
phosphorylation (Chen & Zhong, 2013).  While these deposits within the brain are a hallmark 
feature of AD, medications targeting their clearance have shown minimal, if any cognitive 
improvements (Chen & Zhong, 2013).  Instead of treating the proverbial ‘smoke,’ proactive 
Type 3 Diabetes support has the possibility of providing therapeutic strategies to treat the ‘fire,’ 
also known as multifaceted inflammatory precursors from a chronic perspective.  This may also 
open the door to integrative treatments that merge modern medical science with metabolic 
mitochondrial support in targeting the disease at the core of its inflammatory cascade (See 
Appendix I), (Stein, Schettler, Rohrer & Valenti, n.d.).     
Since much of the previous AD-specific clinical trials have yielded less than hopeful 
results regarding potential pharmaceutical therapies, future research should continue to examine 
insulin-based therapies as multitargeted drugs (De Felice et al., 2014).  This can provide 
restorative potential for both age-related insulin signaling deficits while targeting ApoE(4) 
carriers before detrimental damage ensues (De Felice et al., 2014).  Intranasal insulin may 
provide opportunities for current AD patients and possibly reestablish healthy insulin function 
since this has been found to be the “preferred route for central nervous system delivery” (De 
Felice et al., 2014).  A main benefit of this delivery route is that “circulating levels of insulin or 
glucose” are not normally impacted (De Felice et al., 2014).  Regardless of the AD therapy, the 
true prospects lie in identifying the complex molecular links between AD and diabetes (De 
Felice et al., 2014).  This can allow further understanding and interpretation of “the mechanisms 
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underlying neuronal dysfunction in AD” while birthing much needed interventions for control 
and possibly, harnessing this connection for prevention (De Felice et al., 2014).   
Therapeutic Approaches to Type 3 Diabetes 
Nutraceuticals.  One field of research that has dramatically improved the quality of life 
in both Type 2 Diabetics and AD patients has focused on natural compounds known as 
nutraceuticals relatively annulled of harmful pharmaceutical side effects (De Matos, De Macedo 
& Rauter, 2017).  Prior nutraceutical research has identified curcumin as a brain permeable 
compound with the ability to target abnormal protein aggregates (De Matos, De Macedo & 
Rauter, 2017).  Curcumin may also thwart “proapoptotic signaling pathways in primary 
hippocampal neuron cultures” (De Matos, De Macedo & Rauter, 2017).  Forthcoming research in 
improving bioavailability of curcumin may have the potential to lift the veil on promising natural 
substances for AD patients.  Techniques to boost absorption include combining it with piperine, 
or creating supplements containing water-soluble analogues (De Matos, De Macedo & Rauter, 
2017).   Previous research has also shown the benefit of metformin in mice when coupled with 
curcumin and piperine supplementation, particularly regarding enhanced insulin sensitivity, 
signaling, and better systemic glucose tolerance (De Matos, De Macedo & Rauter, 2017).  It is 
abundantly clear that both the “nutraceutical and pharmaceutical development of structures 
should be highly encouraged” to improve pharmacokinetic profiles and efficacy with “higher 
selectivity toward desired molecular targets” (De Matos, De Macedo & Rauter, 2017).   
 Antioxidant Activity.  There have been too few human epidemiological studies 
examining high intake of fruits and vegetables specifically regarding AD, which suggests the 
vital need for future endeavors pertaining to cognitive decline (Stein, Schettler, Rohrer & 
Valenti, n.d.).  However, the anti-inflammatory benefits of fruits and vegetables have been 
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widely publicized for decades, particularly regarding antioxidant action in reducing 
inflammatory damage (Stein, Schettler, Rohrer & Valenti, n.d.).  Rodent research has linked 
various vegetables and fruits as protective “against cognitive and brain neuropathology from 
dietary oxidative stress” due to innumerable bioactive constituents like carotenoids, antioxidant 
vitamins, polyphenols and flavonoids (Stein, Schettler, Rohrer & Valenti, n.d.).  It has also been 
established that diets void of antioxidants in fruits and vegetables, like the Westernized diet 
coupled with sedentary habits, have the potential to be independent risk factors for disease 
etiology and cognitive decline (Stein, Schettler, Rohrer & Valenti, n.d.).   
The need for prospective antioxidant research has been great, mainly because “studies on 
the effects of vitamin C and E supplements have generally been negative” (Stein, Schettler, 
Rohrer & Valenti, n.d.).  This suggests that future research should incorporate food-based 
support to examine the symbiotic relationship between these constituents physiologically (Stein, 
Schettler, Rohrer & Valenti, n.d.).  Major problems have arisen in vitamin E research because of 
the complexities of the tocopherol family.  Vitamin E-based supplements have customarily been 
comprised of one or two of “at least eight naturally occurring forms of tocopherol” that may or 
may not be physiologically bioactive when isolated (Stein, Schettler, Rohrer & Valenti, n.d.).  
Another issue is that most of our current research on vitamin E focuses on tocopherols, instead of 
tocotrienols, which may provide better and more consistent results.  According to Muller, Theile 
and Bohm, tocotrienols may exhibit increased oxygen radical absorbance capacity with an 
enhanced “reducing ability and radical chain breaking activity” (2010).  At the same time, 
various antioxidant activities are greatly contingent upon circumstances and assays techniques, 
like lipophilic methods in non-polar antioxidants versus hydrophilic means (Muller, Theile & 
Bohm, 2010).  This illustrates the need for more tocotrienol research reflective of appropriate 
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methods based on the constituents of the medium being measured (Muller, Thiele & Bohm, 
2010).   
 Polyphenols.  A separate class of antioxidants known as polyphenols, found in colorful 
fruits and vegetables, has been “suspected to be responsible for some of the health benefits in 
animal and in vitro studies” (Stein, Schettler, Rohrer & Valenti, n.d.).  Blueberries have been 
named as one such category of polyphenols known as acanthocyanins and are implicated in 
preventing and possibly reversing “age-related deficits in neuronal signaling and cognition in 
rats” (Stein, Schettler, Rohrer & Valenti, n.d.).  Polyphenols have also been identified as 
mediators of free radical formation, regulators of nitric oxide, and inhibitors of cancer cell 
propagation (Stein, Schettler, Rohrer & Valenti, n.d.).  Catechins in green tea, dark chocolate and 
unprocessed cocoa have been recognized as a separate class of polyphenols with substantial 
neuroprotective effects in animals (Stein, Schettler, Rohrer & Valenti, n.d.).  Yet, limited 
research has looked “specifically at the possible influence of polyphenols in cognitive decline” 
(Stein, Schettler, Rohrer & Valenti, n.d.).   
While current research has identified roughly 6,000 different polyphenols from various 
families of flavonoids, it has been estimated that we have only scratched the surface with the 
potential therapeutic implications that they provide in vivo (Stein, Schettler, Rohrer & Valenti, 
n.d.).  This is mainly because studies have traditionally focused on single nutrients instead of 
overarching patterns involving synergistic mechanisms available in polyphenol food sources 
(Stein, Schettler, Rohrer & Valenti, n.d.).  Moving forward, “a focus on dietary patterns can 
capture complex interactions among many components that are difficult or impossible to see 
when looking at one or two nutrients individually” (Stein, Schettler, Rohrer & Valenti, n.d.).  
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This has significant potential to advance our understanding of proactive approaches toward 
preventing AD and inhibiting progression (Stein, Schettler, Rohrer & Valenti, n.d.).    
 Omega-3 Fatty Acids. The essential role of omega-3 fatty acids in brain development 
and maintenance has been well recognized, particularly in the past ten years, yet only recently 
“have their effects on brain aging been explored” (Stein, Schettler, Rohrer & Valenti, n.d.).  The 
long-chain omega-3 fatty acid docosahexaenoic acid, commonly referred to as DHA, had 
originally showed promise in the early 1980s in improving memory-related learning in aged 
rodents (Stein, Schettler, Rohrer & Valenti, n.d.).  However, major epidemiological evidence has 
been published since then that supports dietary omega-3s and/or fish consumption as 
substantially beneficial in reducing the risk of Alzheimer’s disease/cognitive decline (Stein, 
Schettler, Rohrer & Valenti, n.d.).  Research has also shown that lower than recommended intake 
has been associated with increased decline in verbal fluency among men and women ages 50 to 
60 (Stein, Schettler, Rohrer & Valenti, n.d.).  One rather large study that examined 2,200 people 
found that the subjects with hypertension and dyslipidemia “showed the greatest benefit” with 
omega-3 fatty acid supplementation when compared with control groups (Stein, Schettler, 
Rohrer & Valenti, n.d.).   
At the same time, research that has examined omega-6 fatty acids in conjunction with 
omega-3 supplementation have found that the inflammatory risks related to high n-6 intake was 
not able to be offset with n-3 consumption (Stein, Schettler, Rohrer & Valenti, n.d.).  Omega-6 
rich oils have been identified as the major source of fatty acids in Westernized eating styles.  
High intake has been found to “more than double the risk of dementia” possibly because 
excessive n-6s have been shown to inhibit cognitive benefits in spite of ample supplementation 
(Stein, Schettler, Rohrer & Valenti, n.d.).  At the same time, it has been estimated that roughly 
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98% of the American population consumes suboptimal amounts of omega-3 fatty acids (Amen, 
2015).  This has identified a major dietary intervention for people at risk for AD or suffering 
from mild cognitive decline as increasing omega-3 intake alone has been unsuccessful at 
restoring cognitive function.  Incorporating high quality fish oils or omega-3 rich fish sources 
while eating fewer processed foods to reduce omega-6 exposure could provide an easy fix to halt 
cognitive decline (Amen, 2015).  Diets rich in omega-3 fatty acids and naturally low in omega-6 
fatty acids may hold the key for nutritional therapy for AD patients (Stein, Schettler, Rohrer & 
Valenti, n.d.). 
Preventing and Reversing Type 3 Diabetes 
The Ketogenic Diet. Omega-3 fatty acids represent anti-inflammatory sources that have 
a positive effect on the body systemically when omega-6 intake is reciprocally reduced (as 
described above).  At the same time, increasing omega-3 fat intake and decreasing processed 
carbohydrate intake when following the ketogenic diet has also shown promise in mitigating 
glucose impairments by providing ketones as complementary energy (Broom, Shaw & 
Rucklidge, 2019).  The ketogenic diet may even diminish and clear beta amyloid plaques within 
the brain, while convalescing damaged mitochondria and reducing universal inflammation 
(Broom, Shaw & Rucklidge, 2019).  New research has shown that glycated ApoE(4) protein and 
faulty insulin signaling leads not only to impaired energy transport for brain tissues, but also 
impaired lipid transportation, mainly cholesterol (Broom, Shaw & Rucklidge, 2019).  By 
inducing a chronic ketogenic state through carbohydrate restriction, the body utilizes ketones as a 
primary source of fuel within the body and more importantly, the brain (Broom, Shaw & 
Rucklidge, 2019).  Ketone production can override shortfalls with insulin production and faulty 
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carbohydrate transport, which has implicated this style of eating as an effective treatment for AD 
(Broom, Shaw & Rucklidge, 2019).   
Lifestyle Support.  There is no pharmaceutical intervention that has ever existed that has 
been more potent in improving overall vasculature throughout the body, than exercise (Amen, 
2015).  When blood flow is improved, the heart works more efficiently, allowing blood cells to 
naturally widen to increase healthy blood flow (Amen, 2015).  We previously discussed 
mitochondrial dysfunction as a hallmark feature of type 3 diabetes and cognitive decline (See 
Appendix J).  Amazingly, exercise produces more mitochondria due to increased energy needs.  
Yet the most dynamic connections exist within the brain, between the cerebellum and the 
prefrontal cortex, which both show activation within the frontal lobes (Amen, 2015).  At the 
same time, the size of the hippocampus in people who exercise regularly is notably larger than 
non-exercisers, displaying the neurogenic affect of physical activity (Amen, 2015).  It has been 
hypothesized that the way to amp up brain derived neurotrophic factor, allowing neurogenesis or 
the growth of new brain cells, is through moderate, habitual exercise (Amen, 2015).  At the same 
time, exercise is one of the most effective interventions for restoring insulin sensitivity while 
lowering peripheral insulin concentrations (Wood & Setter, 2010).  In a world with little to no 
interventions for AD, exercise remains the only proven neuroprotective therapy because of 
several mechanisms (Wood & Setter, 2010).  But most importantly, exercise triggers the 
production of brain-derived neurotrophic factor which facilitates the growth of new brain cells, 
known as neurogenesis (Wood & Setter, 2010).  This also has extensive implications for AD 
patients and type 2 diabetics thanks to increases in quality of life, neurochemical messaging 
within the brain, restorative power over insulin resistance, and the ability to clear beta-amyloid 
plaques in certain individuals (Wood & Setter, 2010).   
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Brain-Gut Connections. It is becoming increasingly difficult to discuss any 
inflammatory disease without mentioning that our 60 trillion human cells house ten times more 
bacterial cells than human cells, meaning our cells are constantly mediated by bacteria (Amen, 
2015).  With this emerging knowledge, we have only just begun to uncover the connections 
between the gut microbiome and systemic health.  These microenvironments within our gut 
includes resident bacterial populations that contain characteristic genetic material while 
producing a plethora of metabolic byproducts (Bonfil et al., 2016).  The capacity theses microbes 
play as regulators of systemic inflammation to every single body system has yet to be realized 
(Bonfil et al., 2016).  Knowing that human cells belong not to us but to bacterial colonies that 
can influence mood, hormonal balance, vitamin and mineral absorption, production and most 
importantly, systemic inflammation, can help us harness gut health as a foundation to brain 
health (Bonfil et al., 2016).  Underlying inflammation has been identified as a hallmark feature 
of both AD and type 2 diabetes, which has brought up the potential of interventions that “balance 
the gut microbiome and reduce inflammation” naturally (Bonfil et al., 2016).   
Genetic modification of seeds and crops in the United States is a major hot topic issue 
because these foods are sprayed with glyphosate as a pesticide (Amen, 2015).  However, the 
chemical compounds in glyphosate disrupt the gut microbiome, potentially triggering 
inflammation and even leaky gut as the cell lining recedes (Amen, 2015).  This chronic gut-
mediated inflammation continues to perpetuate as pesticide laden foods are consumed, disrupting 
the gut microflora and fostering a vicious cycle (Amen, 2015).  Research shows that people who 
consume a Westernized diet have dramatic increases in excretion of glyphosate metabolites, 
which significantly alters the natural synergistic nature of the gut microbiome (Amen, 2015).  
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The biggest offenders in the standard American diet include corn, soy, sugar, and vegetable oils 
with pro-inflammatory fatty acid profiles (Amen, 2015).   
While we have only scratched the surface of the gut brain connection, animal research 
has identified that positive changes within the microbiome of mice “positively impacted neuronal 
pathways in their brains, slowing cognitive decline and the progression of Alzheimer’s disease” 
(Bonfil et al., 2016).  Prior studies have looked specifically at Bifidobacterium strains in 
transgenic mouse models with early stages of AD, which was found to induce anti-inflammatory 
activity by “negatively modulating mRNA levels of pro-inflammatory cytokines” (Bonfil et al., 
2016).  The benefits that have been illustrated further in mouse models have included reduced 
levels of cytokines leading to decreases in β-amyloid plaque accumulation while reversing 
cognitive decline in AD (Bonfil et al., 2016).  In vitro studies have revealed the capacity of 
certain probiotic strains like Lactobacillus and Bifidobacterium to help produce fundamental 
neurotransmitters including gamma-aminobutyric acid (GABA), and acetylcholine for further 
mediation of neurological function (Bonfil et al., 2016).  At the same time, these bacteria 
generate aromatic amino acids like tryptophan and tyrosine, which are vital in neurotransmitter 
synthesis (Bonfil et al., 2016).  These are the first amino acids to be destroyed by glyphosate, 
mentioned in the beginning of this section (Bonfil et al., 2016).  Although animal research has 
been unable to directly correlate these findings to humans, this evidence holds significant 
potential for future research in microbiota-related interventions as another modifiable strategy in 
the treatment and prevention of AD (Bonfil et al., 2016).   
AD Patients Without Type 2 Diabetes  
The Obesity Paradox. Diabetes research has revealed that nearly 80% of all individuals 
diagnosed with type 2 are obese (Chadt et al., 2018).  However, not every obese individual 
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develops type 2 diabetes related to hyperglycemia, which reveals the need for more research into 
these unknown complexities (Chadt et al., 2018).  According to Chadt et al. (2018), “the 
molecular mechanisms underlying these complications are still poorly understood” but there are 
a number of hypotheses worth mentioning here.  The “inflammation hypothesis” in regard to 
obesity ascertains that “a state of chronic inflammation produced by infiltrating macrophages in 
adipose tissue exert pathological changes” (See Appendix K), (Chadt et al., 2018).  The most 
notable changes occur in “insulin-sensitive tissues and β-cells” as described previously in this 
section (Chadt et al., 2018).   A second hypothesis in explaining type 3 diabetes in non-diabetics 
includes the “lipid overflow hypothesis” which indicates that “obesity may result in increased 
ectopic lipid stores due to limited capacity of adipose tissue to properly store fat” (See Appendix 
L), (Chadt et al., 2018).  These lipid components “and their metabolites may exert cytotoxic 
effects on peripheral cells” resulting in insulin resistance, and apoptosis (Chadt et al., 2018).  
While more research is needed to support obesity-specific genetic alterations in leptin and 
cholesteryl ester transfer protein (CETP), some studies have shown increased AD risk factors in 
carriers of the 1405V polymorphism within the CETP gene (Murphy et al., (2012).  Faulty leptin 
signaling, which is a satiety-inducing hormone, has also been implicated in the pathogenesis of 
obesity and AD (Marwarha & Ghribi, 2012).  According to Marwarha and Ghribi (2012), leptin 
receptors are mainly located throughout the hippocampus, and as low expression fosters 
increased beta-amyloid production along with tau phosphorylation.  Polymorphisms in leptin 
signaling may provide further answers within this arena for current and prospective patients 
(Marwarha & Ghribi, 2012).   
We know that future genetics research will shed more light on the variations in insulin 
signaling within the brain of ApoE(4) carriers, and perhaps it will further our grasp on why some 
  50 
 
 
obese individuals never develop insulin resistance (Chadt et al., 2018).  Nevertheless, this 
directly correlates with the notion that type 3 diabetes can occur in people without type 2 
diabetes or systemic hyperglycemia since its consequences remain sequestered within the brain 
tissues (Hyman, 2016).  Also, of interest are the symptoms of cognitive decline, brain fog, 
forgetfulness and inattention in people without type 2 diabetes with high C-reactive protein, 
which may serve as a direct indicator of neuroinflammation (Amen, 2015).   
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Chapter 3 
Methods and Procedures 
Methods 
 The main search method strategy used internet-based search engines, libraries, and 
databases to examine publications, to research Alzheimer’s disease, insulin resistance, ApoE(4) 
research, and the potential for utilizing the term “Type 3 diabetes” for AD patients.  Another 
search strategy examined assessing the effect of AD treatment through diabetic interventions, 
nutraceuticals, and diabetes-related screenings, published between 2005 and 2019. 
Procedures 
          Search procedure.  A careful review of the literature related to Alzheimer’s disease and 
insulin resistance was conducted.  The review highlighted the following topics: (a) Alzheimer’s 
disease, (b) Types 1 and 2 diabetes, (c) insulin resistance and cognitive decline, (d) Type 3 
diabetes (e) ApoE(4) genetic perturbations, (f) prevention and lifestyle support for Alzheimer’s 
disease, (g) prevention and lifestyle support for diabetes, (h) social and economic consequences 
of Alzheimer’s disease, (i) social and economic consequences of diabetes. 
 Libraries used.  There were two libraries used for the sources search for this paper.  The 
Wahlstrom Library at the University of Bridgeport and the Wiley Online Library were both 
employed for research purposes. 
 Search engines and databases used.  The following databases were used to search for 
the sources for this project.  The databases used were PubMed, EBSCOhost, Google Scholar, and 
Citations and Abstracts for Literature from the National Center for Biotechnology Information 
Division Databases.  
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 Search terms.  Several search terms were used to identify sources for this project.  The 
search terms included (a) Alzheimer’s disease, (b) cognitive decline and dementia, (c) Type 1, 2 
and 3 diabetes, (d) insulin resistance, (e) risk factors in neurodegeneration, (f) prevention 
strategies for diabetes, (g) prevention strategies for Alzheimer’s disease, and (h) anti-
inflammatory nutraceuticals.  
 Boolean strings.  Boolean strings were considered for the literature search.  Three 
Boolean strings were used:  Alzheimer’s disease AND insulin resistance AND type 3 diabetes. 
 Age of the sources.  The significant literature has been reviewed.  Sources from the last 
twenty-one years have been considered for inclusion in the review of literature, mainly for 
comparative purposes.  Pertinent historical or seminal articles have also been considered, 
specifically to shed light on the discovery of Alzheimer’s disease.   
 Inclusion criteria.  There were four inclusion criteria.  Inclusion criteria included (a) 
literature published since 2008, except historical sources; (b) English-language text; (c) peer-
reviewed articles; and (d) Web sites relating to Alzheimer’s disease, insulin resistance, types 1, 2 
and 3 diabetes mellitus.  The authenticity of the information utilized from the internet was 
critically appraised based on (a) authorship; (b) publishing body; (c) date of webpage 
publication; (d) objective reasoning; (e) point of view or bias; and (f) accuracy and verifiability 
of the information presented based on references.   
 Exclusion criteria.  There were four exclusion criteria.  The exclusion criteria included 
(a) literature published before 2008, except historical sources; (b) text not published in English; 
(c) articles not peer reviewed; and (d) Web sites not relating to Alzheimer’s disease, insulin 
resistance, types 1 and 2 diabetes mellitus.   
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Chapter 4 
Results 
This literature review has provided substantial evidence that while AD is a complex 
disorder, there is a plethora of irrefutable research that supports viewing it as type 3 diabetes.  
Some of these commonalities, to name a few, include (a) oxidative stress, (b) hyperglycemia, (c) 
insulin resistance, and (d) endothelial dysfunction (de Matos, de Macedo & Rauter, 2017).  There 
is also substantial evidence that type 2 diabetes is fundamentally attributable to lifestyle factors 
and can be reversed and prevented (Wang & Ding, 2008).  This information has the power to 
breathe new life into current AD research efforts with fresh optimism for prospective studies that 
can focus on AD as type 3 diabetes.  At the same time, we have expanded our knowledge of 
brain neurochemistry particularly within the last decade and we now know that brain scans of 
people with chronically high levels of blood glucose have shown detrimental effects on brain 
structure (Kerti, et al., 2013).  These changes predominantly occur within the hippocampus or the 
memory center of the brain (Kerti et al., 2013).  This phenomenon has even been identified in 
people without a formal type 2 diabetes diagnosis and has suggested that the hippocampus is 
particularly susceptible to instabilities in glucose regulation (Kerti et al., 2013).  Deficits in both 
short-term and long-term recall have been hallmark symptoms of cognitive decline, as identified 
by Dr. Alzheimer in his initial protocol for suspected patients (Stein, Schettler, Rohrer & Valenti, 
n.d.).  This is further evidence that the asymptomatic nature of type 2 diabetes can wreak silent 
but deadly havoc on neurocognition. 
Regarding type 3 diabetes, the evidence directly identifies chronic levels of high glucose 
as a main inflammatory marker, which takes a major toll on every organ system by reducing 
normal signaling and starving healthy cells from receiving the appropriate fuel for survival 
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(Boles, Kandimalla & Reddy, 2017).  Like type 2, type 3 diabetes, has been linked to “metabolic 
derangements of carbohydrates, lipids, proteins” coupled with cognitive decline in the presence 
of excessive oxidative stress from insulin resistance and faulty mitochondrial signaling within 
the brain (Mittal & Katare, 2016).  According to Pocernich and Butterfield, “the ratio of oxidized 
to reduced glutathione is utilized as a measure of intensity of oxidative stress” (2012).  The 
higher the ratio favors oxidation, the more extensive the protein oxidation and free radical 
formation (Pocernich & Butterfield, 2012).  Glutathione acts as one of the most potent 
antioxidants in the body and increasing levels has long been considered a therapeutic strategy in 
AD treatment as well as prevention (Pocernich & Butterfield, 2012).   
Extensive amounts of current literature have recognized the increased risk factor for the 
development of Alzheimer’s disease in people with type 2 diabetes (Heerema, 2018).  
Correlations have suggested roughly half or more of all type 2 diabetics will develop some form 
of cognitive decline (Heerema, 2018). Evidence examining the characteristic neurofibrillary 
tangles seen in AD has also linked faulty glucose signaling to neuronal death and cognitive 
degeneration (Mittal & Kattare, 2016).  Specifically, type 3 diabetes has been identified in the 
phosphorylation of tau proteins through increased glycogen synthase kinase signaling, resulting 
in mitochondrial malfunction and significant decreases in energy production, (Mittal & Katare, 
2016).   
It has been made abundantly clear that increasing patient education of type 3 diabetes and 
focusing on prevention strategies would decrease disease burden, increase quality of life and at 
the same time, save trillions of dollars in healthcare spending (Boles, Kandimalla & Reddy, 
2017).  While clinical medicine has been slow to acknowledge the fact that type 2 diabetes is a 
manifestation of adjustable factors, it has been even slower to connect these same dots regarding 
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AD (Boles, Kandimalla & Reddy, 2017).  Only recently has research correlated the metabolic 
disturbances in AD and diabetes, birthing the term type 3 diabetes, which may explain the stalls 
in recognition and the shortcomings of clinical trials thus far.   
The evidence has emphasized an unequivocal need to view AD as type 3 diabetes so that 
proactive screening efforts can become commonplace, particularly for ApoE(4) carriers.  There 
is no doubt that in patients who have the ApoE(4) gene, insulin receptor signaling becomes 
trapped inside the neuron, specifically within the endosome, due to the production of the 
ApoE(4) protein (Zhao et al., 2017).  This deflects signaling by blocking receptors located on the 
surface of the neuron, stalling insulin utilization further (Zhao et al., 2017).  As the process 
continues, the ApoE(4) protein continues to “clump,” further perpetuating the cycle and resulting 
in cellular starvation and ultimately, apoptosis (Zhao et al., 2017).  If roughly 20% of the 
population has this genetically-rooted error in “insulin trafficking,” it is abundantly clear that 
genetic screening can identify this risk factor.  Since ApoE(4) carriers have a substantially 
augmented risk for AD, particularly when coupled with type 2 diabetes and the natural aging 
process, genetic screenings can identify candidates so that sustainable interventions can take 
place (Zhao et al., 2017).   
The literature has also established the fact that neuronal death perpetuates the loss of the 
ability of the CNS to produce appropriate growth factors, greatly reducing insulin expression, 
while favoring the development of tau mRNA and amyloid precursor proteins as compensatory 
mechanisms (Steen et al., 2005).  The oxidative cascade in both AD and type 2 diabetes has been 
extremely well studied.  However, in many patients who never had diabetes, the phenomenon 
remained sequestered to the brain, distinct from both type 1 and type 2 diabetes (Steen et al., 
2005).  This further underscores the need for an increased awareness of type 3 diabetes, since 
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cognitive degeneration can develop in people without an official diagnosis of type 2 diabetes 
(Steen et al., 2005).  Moreover, the literature has been well established in utilizing diminished 
baseline glucose metabolism as a sensitive biomarker in examining and measuring AD-related 
cognitive decline” (Godoy et al., 2014)  At the same time, the FDA has already recognized the 
need for developing multitargeted pharmaceutical support for current and future AD patients.  
These two factors alone carry major weight in the emerging field of type 3 diabetes so that 
strategies can “slow down or attenuate metabolic deficits” observed in AD (Godoy et al., 2014).   
The literature has also directly identified defective glucose metabolism and neural insulin 
resistance as early indicators of AD (An, Varma, Varma, Casanova, Dammer, Pletnikova et al., 
2018).  The acuteness of AD pathology may hinge on GLUT3 levels; the lower the levels, the 
more severe the AD symptoms (An et al., 2018).  Ample evidence has also found that 
“overexpression of GLUT-1” improves glucose metabolism and reduces AD-associated 
cognitive alterations (An et al., 2018).  This evidence also indicates the possible therapeutic 
effect of restoring normal glucose metabolism within the brains of AD patients.  It is well 
established that the pathology of AD occurs decades before clinical onset, so this evidence 
identifies the need to define specific mechanisms behind failure of glucose transporters within 
the brain and not just compensatory mechanisms like plaque formation or tau phosphorylation 
(Duran-Aniotz & Hetz, 2016).   
There has also been undeniable evidence documenting the downstream effects of chronic 
insulin resistance, particularly “the weakening of insulin transition by the blood brain barrier” 
(Leszek et al., 2017).  Other possible effects include facilitating the modulation of tau-protein 
formation due to activation of insulin resistant reductions in phosphorylating kinase activity 
(Leszek et al., 2017).  Insulin resistance itself has led to (a) mitochondrial abnormalities, (b) 
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oxidative stress, (c) “reductions in synaptic plasticity in the hippocampus” and has shown to be 
exacerbated with the natural aging process coupled by a sedentary lifestyle and lack of proper 
nutrition (Leszek et al., 2017).  Moreover, study after study has revealed that the problem can 
also be the solution in the form of anti-inflammatory lifestyle choices combined with anti-
diabetic therapy targeted to normalize insulin signaling within the central nervous system 
(Leszek et al., 2017).  These preventative strategies can reroute insulin resistant pathways and 
possibly foil AD (Leszek et al., 2017).   
Major epidemiological evidence has also identified the role that dietary choices can play 
in both disease etiology and prevention, particularly concerning nutraceuticals.  Research 
concerning omega-3 fatty acids is no doubt the nutraceutical field where the most extensive 
brain-related research has been documented.  Study after study points to dietary omega-3 fatty 
acid consumption as a substantial mediator in the reduction of AD/cognitive decline (Stein, 
Schettler, Rohrer & Valenti, n.d.).  The literature also highlights repercussions in populations 
who consumer lower than recommended intake, which has been associated with increased 
decline in verbal fluency among men and women ages 50 to 60 (Stein, Schettler, Rohrer & 
Valenti, n.d.).  It has also been recognized that subjects with the greatest amount of inflammation 
in the form of hypertension and dyslipidemia “showed the greatest benefit” with omega-3 fatty 
acid supplementation (Stein, Schettler, Rohrer & Valenti, n.d.).  At the same time, irrefutable 
evidence has found that the inflammatory risks related to high n-6 intake was not able to be 
offset with n-3 consumption (Stein, Schettler, Rohrer & Valenti, n.d.).  Omega-6 rich oils have 
been identified as the major source of fatty acids in Westernized eating styles, and high intake 
has been found to “more than double the risk of dementia” possibly because excessive n-6s have 
been shown to inhibit cognitive benefits in spite of ample supplementation (Stein, Schettler, 
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Rohrer & Valenti, n.d.).  This has identified a major dietary intervention for people at risk for 
AD or suffering from mild cognitive decline as increasing omega-3 intake alone has been 
unsuccessful at restoring cognitive function.  Diets rich in omega-3 fatty acids and naturally low 
in omega-6 fatty acids may hold the key for nutritional therapy for AD patients (Stein, Schettler, 
Rohrer & Valenti, n.d.).  Abundant research also has shown that it is much easier to protect a 
healthy brain than to try to repair damage once it is widespread.  This highlights the importance 
of preventative measures as providing extremely beneficial implications for current and future 
patients (Colino, 2017).   
Today’s statistics involving AD and diabetes as chronic disease epidemics have shed 
light on the desperate need for improvements in both disease prevention and management.  The 
literature has shown that viewing AD as type 3 diabetes as well as increasing awareness of the 
term have potential to provide sustainable and integrative therapies, allowing patients to become 
invested in their health choices.  This may also help to promote individual accountability and a 
sense of conscientiousness in taking back one’s own health through lifestyle choices (Hu, 2016).  
It remains safe to say that we still have much to learn about the exact correlations and 
downstream effects exhibited in AD, type 2 diabetes and the underlying etiology of type 3 
diabetes.  At the same time, current literature has established the onset of AD as a manifestation 
of largely modifiable metabolic changes that specifically affect the brain.   
Since AD was first identified over 100 years ago, most of the methods that have been 
identified as potential treatments have been disappointing in clinical trials, leaving today’s 
patient with a very limited standard of care.  This is largely due to the lack of correlation of 
common metabolic disturbances, particularly with cerebral glucose metabolism, that have only 
been established within the last decade.  Since the discovery of neurofibrillary formations within 
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the brain, clinical trials have habitually focused on the elimination of plaque deposits or tau 
phosphorylation.  These methods have targeted the proverbial ‘smoke,’ instead of examining 
therapeutic strategies to treat the ‘fire’ also known as multifaceted and chronic inflammatory 
precursors.  The evidence shows that increasing awareness of the progression of type 3 diabetes 
may also open the door to integrative therapies that merge modern medical science with 
metabolic support in targeting the disease at the core of its inflammatory cascade.  It goes 
without saying that redirecting future research efforts to expand the view of AD as a multifaced 
type 3 diabetes will help “break the bottleneck of currently stalled AD research” (Chen & Zhong, 
2013).  The term type 3 diabetes already exists because of the overwhelming evidence that links 
all of the aforementioned diabetes-like factors in the etiology of cognitive decline.  While we 
have yet to even comprehend the full benefit of approaching AD proactively, this research 
highlights the abundant need for increased awareness of type 3 diabetes and resolves the basic 
notion of this dissertation. 
 
 
 
 
 
 
 
 
 
 
  60 
 
 
Chapter 5 
Discussion, Conclusions, Implications, and Recommendations 
Discussion 
A main concentration of this dissertation involves the ability to shed light on both the 
complexity and gravity of Alzheimer’s disease as a multifactorial condition culminating from (a) 
oxidative stress, (b) hyperglycemia, (c) insulin resistance, and (d) endothelial dysfunction (de 
Matos, de Macedo & Rauter, 2017).  All these factors, which have been established as hallmarks 
of type 2 diabetes, have been recognized as contributors of cognitive decline by “blocking or 
reducing blood flow to the brain” (de Matos, de Macedo & Rauter, 2017).  Interestingly enough, 
the production of both beta amyloid proteins and tau proteins characteristic in post mortem 
diagnoses of AD both have pathologies “triggered by hyperglycemia” based on both in vivo and 
in vitro research (de Matos, de Macedo & Rauter, 2017).  Unfortunately, the cumulative effect of 
diabetes coupled with the harmful consequences of the systemic inflammatory cascade has 
resulted in the etiology of preventable chronic diseases that were once almost nonexistent (de 
Matos, de Macedo & Rauter, 2017).  These are many of the reasons we are now in the middle of 
a healthcare crisis (de Matos, de Macedo & Rauter, 2017).  However, this current changing 
healthcare paradigm has led to the publication of more research in the area of type 3 diabetes 
even though future research is still imperative in establishing fundamental connections once a for 
all.  This has placed us at an advantage, thanks to modern technology, brain scans, and years of 
post-mortem findings that have led to the notion of adopting the term ‘type 3 diabetes’ which 
was relatively overlooked even a decade ago.   
Since AD has been examined for more than a century, there has been much 
documentation and observational evidence pertaining to long-term progression of the disease.  
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This has helped fuel prospective studies on various parts of the brain and how they have been 
affected (Kerti et al., 2013).  Correlations from this evidence have further promoted the 
connections between insulin resistance, hyperglycemia and oxidative stress in AD patients (Kerti 
et al., 2013).  This has been identified as a major strength because we now have significant data 
and therapeutic lifestyle support for lowing blood sugar levels through lifestyle management and 
lower carbohydrate intake to improve glucose control and even prevent cognitive decline (Kerti 
et al., 2013).  “Diet-induced changes in markers of glucose metabolism directly correlate with 
increases in memory function,” which has identified daily dietary choices as one of the most 
powerful mediators of health and disease, particularly concerning neurochemistry (Kerti et al., 
2013). This evidence has further identified pathways for potential research in people without 
type 2 diabetes with augmented glucose control.  It has created a possible basis for further 
examination of the effect of lifestyle modifications in both AD progression and prevention (Kerti 
et al., 2013).   
An additional strength in the form of a tentative solution has included our comprehensive 
understanding of “chronically elevated glucose on brain function and structure” based on 
evidence from insulin transport and signaling within brain tissues examined from type 2 
diabetics compared with non-diabetics (Kerti et al., 2013).  Physical activity has long since been 
established as another important lifestyle modification that has the direct ability to lower glucose 
levels in everyone, particularly in type 2 diabetics (Kerti et al., 2013).  This is yet another 
tentative solution in preventing disease advancement (Kerti et al., 2013).  Of particular interest is 
recent research in epigenetics identifying healthy lifestyle choices as main factors that reduce the 
risk for cognitive decline in older adult carriers of the ApoE(4) gene.  This directly implicates 
20% of the population who are projected to be at an augmented risk for AD simply based on 
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genetic predisposition (Lourida et al., 2019).  While more research in this field continues to shed 
light on specific mechanisms, this further illustrates the power that daily lifestyle choices can 
have in genetic signaling regardless of genetic inclination (Lourida et al., 2019).   
Regular exercise has also been linked to optimal mitochondrial functionality within the 
cell, better glucose utilization, and exponential increase in the number of mitochondria present 
(Silzer & Phillips, 2018).  It has also been shown that systemic mitochondrial dysfunction 
“originating from obesity or T2DM or from altered cellular homeostasis” has the potential to 
create a deleterious cascade which ensues in premature cell death along with subsequent 
mitochondrial decay (Silzer & Phillips, 2018).  This knowledge has presented a potential 
therapeutic strategy in targeting mitochondrial health through exercise, lifestyle, supplemental 
support, and blood sugar modulation in order to prevent initial mitochondrial deterioration 
(Silzer & Phillips, 2018).  We have yet to even realize the future implications of targeting 
mitochondrial health.  At the very least, the literature has pointed to the importance of utilizing 
complementary mitochondrial therapy in any progressive inflammatory condition, specifically 
AD and type 2 diabetes (Silzer & Phillips, 2018).   
At this time, there has been little evidentiary support in the form of a pharmaceutical cure 
for AD, however, much research has uncovered numerous threats to cognitive health as well as 
protective influences that have the ability to modulate overall risk (Woodward, 2007).  Thanks to 
these advances in the field, research has established the natural aging process, genetic factors, 
family history, and inflammatory conditions such as diabetes as the top four most-established 
risk factors for the development of AD (Woodward, 2007).  While not all risk factors have the 
ability to be modified, blood sugar and diabetes have responded extremely well to dietary 
interventions and physical activity (Woodward, 2007).  Well-controlled diabetes along with 
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frequent monitoring of blood sugar have the potential to thwart neuronal damage from chronic 
oxidative stress and possibly prevent excessive formation of AGEs (Stein, Schettler, Rohrer & 
Valenti, n.d.).  According to Stein et al. (n.d.), “not unexpectedly, the dietary factors that reduce 
risks of diabetes and cardiovascular disease likewise appear to reduce risk for cognitive decline” 
(p. 124).  This has highlighted nutritional support and education as therapeutic and proactive 
strategies in the prevention of AD, providing further evidence of the notion that AD truly has the 
potential to be considered type 3 diabetes (Stein et al., n.d.).   
Research has shed a great deal of light on type 2 diabetes just within the past two decades 
and with the increasing availability of “a wide range of drugs for managing diabetes and its 
complications, the life expectancy of persons with diabetes is steadily increasing” (Pugazhenthi 
et al., 2017).  At the same time, this has continued to create opportunities in future research to 
solidify the associations between AD and type 2 diabetes, particularly because now, more than 
ever, people have the ability to live longer with a diabetes diagnosis (Pugazhenthi et al., 2017).  
While this has been identified as a positive aspect from a research perspective, the type 2 
diabetes projections in the United States over the next decade have the potential to further 
perpetuate the chronic disease epidemic and have been viewed as anything but positive 
(Pugazhenthi et al., 2017).  Modern research has established type 2 diabetes as largely a disease 
of lifestyle and modifiable factors not only play a major role in prevention, but also in reversing 
the disease (Silzer & Phillips, 2018).  Using this information when examining AD and having the 
ability to view this debilitating disorder as type 3 diabetes has given new hope to the possibility 
of both treatment and prevention where very little hope has been preestablished (Silzer & 
Phillips, 2018).   
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Of all the revealing research in the field of AD, type 2 diabetes, and the interplay of 
chronic inflammation coupled with metabolic disturbances and genetic alterations, more 
questions have arisen than answers.  While much of the evidence has pointed to type 2 diabetes 
as a risk factor for developing dementia, other research has supported the opposite notion, that 
“AD patients are the higher risk factor for type 2 diabetes” spawning the proverbial question of 
‘which came first, the chicken or the egg’ (Leszek et al., 2017).  Many AD and type 2 diabetes 
studies have traditionally included small sample sizes, not particularly representative of the 
general population without the ability to have randomization, which has led to the increased 
potential for confounding factors (Kerti et al., 2013).   
The randomized, controlled trials that have been identified as the gold standard for 
research protocol have been designed to examine a specific and measurable intervention at a 
designated concentration over a predetermined course of time in a controlled environment.  This, 
however, has resulted in the lack of useable data regarding human physiology and real-world 
environmental scenarios where the general population has been exposed to a plethora of 
environmental toxins simply upon waking in the morning.  In relation to nutritional biochemistry 
and physiological interactions to specific factors, RCTs in the pharmaceutical world of AD have 
been extremely disappointing, yielding only a handful of drugs that temporarily thwart 
progression with multiple debilitating side effects (Kerti et al., 2013).  To further complicate 
research up to this point, most lifestyle and dietary studies have been observational and based on 
self-reported measures like 24-hour recalls, food frequency questionnaires and survey 
information related to daily habits (Larson et al., 2006).  Many times, these subjective parameters 
of assessment have the ability to be manipulated to produce favorable outcomes in a given 
patient population, particularly when research is left unblinded (Larson et al., 2006).  This has 
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continued to present as one of the most difficult problems facing research in nutrition and 
lifestyle today.   
Antioxidant research and nutraceutical interventions have produced extremely diverse 
results due to the isolation of constituents that have been meant to work in conjunction with one 
another physiologically (Stein, Schettler, Rohrer & Valenti, n.d.).  This may explain why high 
levels of antioxidant supplementation have been detrimental in some patients since the naturally 
occurring combination of flavonoids has traditionally allowed the regenerative relationship of 
vitamins to thrive in vivo (Stein, Schettler, Rohrer & Valenti, n.d.).  This is especially true when 
considering the ability of vitamin C to regenerate vitamin E and vice versa (Stein, Schettler, 
Rohrer & Valenti, n.d.).  While discussions in nutritional biochemistry have not been included in 
the scope and purpose of this literature review, it is important to identify the potential for single 
antioxidants to become oxidized in vivo unless regenerated by other antioxidants.  This may 
explain the conflicting results in this field of research.   
Another difficulty has been reaching an unreachable population in diagnosing AD, which 
has presented a major barrier in research efforts since a definitive diagnosis has typically 
involved invasive techniques like measuring inflammatory markers in CSF (Chornenkyy et al., 
2018).  To further muddy the waters in the pharmaceutical realm, there has been a desperate 
demand for more “specific inhibitors targeting inflammatory pathways in order to gain maximum 
benefit in prevention or treatment of T2DM and AD at the same time (Mushtaq et al., 2015).  
Pharmaceutical interventions for controlling blood glucose levels and type 2 diabetes have been 
identified as potential mediators of AD (Mushtaq et al., 2015).  However, only thiazolidinedione 
derivatives have been proven to “have the best potential” for improving systemic glucose 
tolerance (Mushtaq et al., 2015).  Unfortunately, these medications have had a track record of 
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extremely severe side effects including further cognitive degeneration (Mushtaq et al., 2015).  It 
has gone without saying that much more research needs to be performed regarding 
pharmaceutical interventions for AD particularly since we have yet to fully establish the etiology 
of the disease in general (Mushtaq et al., 2015).  This may also potentially explain why “no safe 
and effective anti-AD drug to prevent, halt or reverse the progression of AD” has ever existed 
(Mushtaq et al., 2015).   
 Regrettably, one of the biggest problems hindering progress has involved stagnation in 
diabetes prevention particularly in recognizing prediabetes since it has been known to go 
asymptomatic for years and even decades (Ferreira, Clarke, Bomfim & De Felice, 2014).  
Implementations must also be chronically assessed for success in order to accurately identify the 
unique needs of an individual (Ferreira, Clarke, Bomfim & De Felice, 2014).  This has 
conventionally involved lots of manpower, money and government delegation of services, which 
may be difficult to achieve in rural areas with poor access to care (Ferreira, Clarke, Bomfim & 
De Felice, 2014).  We have just begun connecting many dots between overarching mechanisms 
linking AD and type 2 diabetes, prompting the need to publish future human-based research in 
order to tease out various patterns and conflicting data.  For instance, amyloid beta plaque and 
tau protein formation have been commonly observed in postmortem brain analyses (Leszek et 
al., 2017).  However, in some AD diagnoses, their presence has been nonexistent and rather 
sporadic (Leszek et al., 2017).  These controversial findings have further muddied the waters in 
linking these two diseases conclusively.  This has also identified the need for “further studies on 
(a) molecular mechanisms, (b) medicinal chemistry, (c) pathological evidences and (d) 
epidemiological research” involving the entire spectrum of cognitive decline, from early 
indications to late stages of the disease (Leszek et al., 2017).  Having the ability to grasp the 
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“molecular basis of neuronal dysfunction and memory loss” in AD has turned out to be a key 
challenge in the public health arena today.  This will continue to be a problem since diagnosis 
projections have been predicted to upsurge exorbitantly within the next ten years, with treatment 
options severely deficient (De Felice et al., 2014).   
The fact that the brain has been identified as an “insulin sensitive organ” is still a 
relatively new concept (Felice et al., 2014).  Within the last two decades, modern science has just 
outlined the extent insulin plays as a main facilitator for “synaptic plasticity, learning, and 
memory” (De Felice et al., 2014).  AD has remained a perplexing disorder “in search of 
mechanisms that fully explain memory loss and lead the way to development of effective 
therapies” that have remained unable to thwart progression of the disease (De Felice et al., 2014).  
It has also remained virtually impossible to develop controlled human studies that fully mimic 
the ambiguities of varying environments in order to account for “any influence that negatively 
impacts cognition” (Chornenkyy et al., 2018).  This further highlights the controversies behind 
environmental factors and risk of developing AD (Chornenkyy et al., 2018).  Evidence about AD 
pathophysiology in animal research has been abundant, however, another major weakness in the 
literature has involved the lack of evidence “upstream of NFT formation and beta-amyloid 
deposition” (Chornenkyy et al., 2018). These upstream components of insulin signaling within 
the brain have yet to be fully identified in AD pathogenesis (Kandimalla et al., 2017).  There 
have also been more questions raised regarding long-term insulin action and potential related to 
“long-term depression across synaptic contacts” in order to fully outline “how stimulators of 
insulin signaling act to promote neuroprotection in AD brains” (Kandimalla et al., 2017).   
Other uncertainties have arisen in genetic-based research, particularly regarding the 
ApoE(4) connection to blocked insulin signaling with the brain (Kandimalla et al., 2017).  This 
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has included queries as to whether other genes have played a role and whether or not animal 
studies have the ability to parallel to humans (Kandimalla et al., 2017).  The lack of genetic 
research regarding ApoE(4) in humans has presented major problems with drawing any real 
conclusions and formally identifying carriers with potentially augmented risk factors 
(Kandimalla et al., 2017).  While research in genetics has continued to show promise in the field 
of AD, discoveries have been slow-coming, expensive, and extremely time consuming.  This 
information has been of little solace to current patients who have been given a limited protocol 
and timeline.   
In contemporary societies, AD has remained so common that many cultures have viewed 
it as a normal age-related consequence destined to afflict anyone and everyone randomly (Larson 
et al., 2006).  Unfortunately, much of the available research in AD has also echoed these 
sentiments by excluding patients with senile dementia that has traditionally been explained as an 
age-related occurrence and not truly a disease (Godoy et al., 2014).  Little research has been 
done to truly elucidate the biological basis behind preventative strategies (Larson et al., 2006).  
These include blood sugar modulation, healthy eating habits, exercise and increased oxygen 
delivery in improved quality of life for the aging populace (Larson et al., 2006).   While newly 
emerging fields like epigenetics have turned the ‘genetics = destiny’ mentality completely on its 
head, there have been major weaknesses and even disconnects in patient education regarding 
disease risk and prevention (Larson et al., 2006).  It has not helped that the current healthcare 
paradigm has continued to forego evidence of environmental exposures on genetic inclinations 
and signaling (Larson et al., 2006).  Unfortunately, the current healthcare paradigm focuses on 
reactive medicine where people live their lives the way they choose without thinking about 
repercussions down the road.  Once a problem arises, like cognitive decline, the first thought is 
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medication to ameliorate the problem (Amen, 2015).  However, there is no magic pill especially 
when it comes to AD (Amen, 2015).  Failure to educate patients on modifiable lifestyle factors 
has led to many missed opportunities to sustainable solutions that not only have the potential to 
prevent disease, but also have the capacity to reduce disease burden in general (Larson et al., 
2006).  
In our modern society, it has been customary for companies to introduce hundreds of new 
chemicals and toxins onto the consumer market on a weekly basis (Fell, 2018).  This has 
produced countless new barriers in human research regarding type 3 diabetes due to the 
subjective nature of environmental factors along with age and exposures (Fell, 2018).  For 
instance, certain pesticides like DDT have been banned since 1972 when identified as potential 
neurotoxins and carcinogens (Fell, 2018).  However, before being restricted, DDT had 
widespread use globally and has remained legal in several countries (Fell, 2018).  This has 
significant pertinence to AD patients, particularly from the baby-boomer generation and beyond 
because DDT was legal and present throughout their adolescent and youth years (Stein, 
Schettler, Rohrer & Valenti, n.d.).  Epidemiological research that has examined PCBs in older 
adults has identified major cognitive deficits, yet they have been criticized for being mostly case-
control studies that have lacked longitudinal, prospective research (Stein, Schettler, Rohrer & 
Valenti, n.d.).  While many studies have continue to draw conclusions among chemical exposure 
and AD, methodologic problems, confounding factors, difficulty distinguishing exposed 
participants from non-exposed participants, misclassifications from low exposures, and “lack of 
long-term exposure biomarkers” have all continued to create weaknesses in current literature 
(Stein, Schettler, Rohrer & Valenti, n.d.). 
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Conclusion 
The outcomes of this research reveal the dire need to examine AD as a possible type 3 
diabetes in order for effective AD therapies to emerge (Godoy et al., 2014).  While future 
evidence has the potential to further our understanding of AD etiology, pathology and reveal 
undeniable evidence to adopt the term ‘type 3 diabetes,’ the connections that have been 
uncovered up to this point are undeniable.  As the population of the world continues to grow as 
well as age, proactive efforts must be made in order to prevent detrimental downstream effects of 
chronic inflammation with lifestyle and education (Godoy et al., 2014).  Arming patients with 
this information while also examining the potential benefit of multitargeted medications can 
provide support and possibly improve quality of life (Godoy et al., 2014).  There have been 
numerous associations made between “neurodegenerative diseases, such as increased oxidative 
stress, decreased autophagy and formation of misfolded proteins, impaired neuronal metabolism 
and mitochondrial dysfunction” (Godoy et al., 2014).  Of particular interest for prospective 
research are both the chronic effects of insulin resistance and faulty signaling based on ApoE(4) 
genetic discoveries (Godoy et al., 2014).   
In conclusion, this research has highlighted the need to increase awareness of type 3 
diabetes.  The gravity of Alzheimer’s disease and type 2 diabetes as growing epidemics that have 
been attributable to both chronic and acute diseases and millions of preventable deaths each year 
is backed with irrefutable statistical evidence from the field.  Alzheimer’s Disease has already 
been identified as the sixth leading cause of death in the United States, and the fifth leading 
cause of mortality in people 65 and older (Kandimalla, Thirumala & Reddy, 2017).  
Unfortunately, diabetes is following right behind AD as the 7th leading cause of mortality and 
has been projected to affect almost 400 million people by the year 2030 (Centers for Disease 
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Control & Prevention [CDC], 2017).   At the same time, type 2 diabetes has remained one of the 
most adjustable risk factors for the development of Alzheimer’s Disease (Pugazhenthi, Qin & 
Reddy, 2017).  It has been well ascertained in the literature that Type 2 Diabetes is largely 
preventable (CDC, 2017).  While the specific mechanisms between AD and all forms of diabetes 
remain convoluted and unclear, increasing the awareness of AD as a third form of diabetes has 
the potential to provide a plethora of proactive and therapeutic strategies to current patients.  
These include prevention through weight control, healthy lifestyle choices that can reduce AGE 
formation and anti-inflammatory nutritional support to thwart the oxidative cascade both 
systemically and within the brain (Wang & Ding, 2008).   
This research has focused on selected literature related to Alzheimer’s Disease, 
overlapping mechanisms related to diabetes and the potential for increasing awareness of the 
term ‘type 3 diabetes’ in relation to AD.  Another purpose of this literature review has been to 
investigate the available evidence regarding commonalities between type 2 diabetes and AD and 
to examine the brain-specific effects of chronic hyperglycemia considering a type 3 diabetes 
term.  There has been growing literature published that has linked insulin resistance, which has 
traditionally been implicated in type 2 diabetes, “to the pathogenesis of AD” and has emerged as 
a major risk factor for cognitive decline due to neurologically-specific mechanisms that have 
been identified to impair normal blood flow and result in vascular lesions (Chornenkyy et al., 
2019).  One final purpose of this research has been to provide potential recommendations for 
modulation of AD with multitarget pharmaceuticals, combination therapies, adjuvant nutrition 
and lifestyle support, and nutraceuticals.  The only way the implications of type 3 diabetes can be 
fully realized is if the healthcare system acknowledges, supports, and plans a proper transition 
regarding application along with constructing a system that better supports proactive services 
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while placing critical needs at the forefront (Hu, 2016).  Future goals have also been integrated 
below, which have included specific research topics along with the overarching requirement for a 
profound grasp of how “metabolic perturbations contribute to AD-type pathology” to develop 
innovative treatment strategies and foster prevention of type 3 diabetes (Chornenkyy et al., 
2019).   
Implications 
The research findings have several significant implications.  First, increasing the 
knowledge and awareness of the term type 3 diabetes has the potential to pave the way for 
disease treatment, prevention and possibly even deliver a cure (de la Monte & Wands, 2008).  
Original AD literature that has revealed “impairments in cerebral glucose utilization and energy 
metabolism represent very early abnormalities that precede or accompany the initial stages of 
cognitive impairment” which has played a significant role in the etiology of AD (de la Monte & 
Wands, 2008).  These initial connections from AD research very early in the field have spawned 
even more studies to examine AD as a “form of diabetes mellitus that selectively afflicts the 
brain” (de la Monte & Wands, 2008).  Viewing AD as type 3 diabetes would provide real 
solutions that have been far and few to existing patients (de la Monte & Wands, 2008).  
Currently, there have been no particular treatments with established efficacy in counteracting 
cognitive decline and/or AD, so the implications of identifying AD as a disorder with an etiology 
rooted in faulty insulin signaling and irregular energy pathways could be critical in disease 
management (Wood & Setter, 2010).  At the same time, patients could be provided with 
strategies that target glycemic control (Wood & Setter, 2010).  Contrary to AD, there have been 
a plethora of pharmacological therapies designed to target and manage diabetes (Wood & Setter, 
2010).  One such drug class known as peroxisome proliferator-activated receptor-gamma 
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agonists or PPAR-gamma agonists have been heavily studied regarding glucose and lipid 
metabolism (Wood & Setter, 2010).  This drug class has shown promise as potential modulators 
of inflammation, which has been established as a well-recognized risk factor for AD (Wood & 
Setter, 2010).  While these medications have yet to be approved by the FDA as effective AD 
treatment, they may have the ability to prevent cognitive decline in patients with diabetes (Wood 
& Setter, 2010).  They may also provide a proactive intervention for current diabetic patients 
who already have an increased risk for cognitive decline (Wood & Setter, 2010).   
Additionally, one of the most successful yet disregarded methods of naturally reducing 
insulin resistance has been exercise, which has been proven to “improve insulin sensitivity and 
lower peripheral insulin levels” (Wood & Setter, 2010).  New evidence shows that aerobic 
activities may provide the most health benefits (Pederson, 2018).  Simple exercises like 
vigorously walking 75 minutes per week showing the greatest benefit when compared to high 
intensity interval training, yoga, and combination activities (Pederson, 2018).  The positive 
health implications of daily exercise for people with AD have not been discussed enough, as 
physical activity “independent of weight, is associated with a lower risk of AD, making it the 
only proven neuroprotective therapy” (Wood & Setter, 2010).  Exercise has been established as a 
hallmark of any healthy lifestyle, with remarkable beneficial effects for the entire body.  Yet, the 
most specific positive effects have been exhibited within the brain.  Exercise has the potential to 
“promote the clearance of beta-amyloid proteins and increase brain -derived neurotrophic factor 
vital to cognition and neuronal survival” in patients with AD (Wood & Setter, 2010).  Exercise 
has a significant aptitude to increase quality of life and decrease disease burden in general and 
should be included in any patient protocol, particularly because it has proven advantageous 
effects within the brain and at the cellular level.   
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Furthermore, it has been established that the disease burden caused by both diabetes and 
AD has resulted in epidemic numbers, with diabetic diagnoses projected to reach 366 million 
people by the year 2030 (Leszek et al., 2017).  To put this into perspective, these numbers make 
up almost 5% of the total world population (Leszek et al., 2017).  AD has remained the number 
one most frequent form of dementia and has affected “more than 36 million people worldwide” 
(Leszek et al., 2017).  At the same time, most people are completely unaware of the modifiable 
risk factors that have demonstrated significant reductions in “key triggers of oxidative and 
inflammatory damage” leading to “synaptic dysfunction and neuronal death” (Leszek et al., 
2017).  New “multitarget therapies” may have the potential to confront both conditions when 
administered along with adjuvant lifestyle support in preventing the progression of each disease 
(Leszek et al., 2017).  This integrative support has the potential to diminish or possibly inhibit 
aggregate neurodegeneration that has been documented in “the earliest stages of T2D” (Leszek et 
al., 2017).  The most powerful screening tools in clinical medicine include HbA1C, fasting 
glucose and C-peptide levels as mentioned in chapter 2.  Screening patients for prediabetes has 
the potential to reach even more people before the inflammatory cascade has time to induce 
irreversible damage to the brain (Leszek et al., 2017).  This is especially true considering the 
cognitive deterioration that has been documented in prediabetic patients where “fasting glucose 
levels are abnormally high but below the threshold for diabetes” (Leszek et al., 2017).  
Uncovering inflammatory markers well in advance of downstream cumulative effects has the 
potential to provide desirable therapeutic lifestyle support for an emergent public health crisis 
(Leszek et al., 2017).  
Studies that have examined a single therapeutic intervention unaccompanied, (i.e. one 
pharmaceutical medication), have failed to recompense the accumulative impairments in both 
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disease pathologies (Leszek et al., 2017).  This has the potential to explain the disappointing 
results in AD research to date (Leszek et al., 2017).  AD has been identified as extremely 
multifaceted, requiring treatment options that target multiple inflammatory cascades that utilize 
“more than one bioactive compound” (Leszek et al., 2017).  Key areas for current and future 
research include the expansion of advanced therapies “able to tackle multiple targets at once” 
(Leszek et al., 2017).  Increasing awareness of Type 3 Diabetes by integrating lifestyle and 
nutritional support into patient protocol provides multitargeted support without pharmaceutical 
side effects (Leszek et al., 2017).   
Finally, it has been ascertained that not everyone who has been diagnosed with type 2 
diabetes will go on to also be diagnosed with AD (Colino, 2017).  At the same time, not 
everyone with AD has type 2 diabetes (Colino, 2017).  However, statistically speaking, diabetics 
have double the risk of developing AD within their lifetime and people with “poorly controlled 
blood sugar and central obesity” have even greater risk of cognitive decline (Colino, 2017).  
While these facts are well established in the literature, many patients have not been provided 
with this information or educated on the neurotoxic dangers of chronic inflammation (Colino, 
2017).  These shortcomings in patient education can have a profound effect both on short-term 
and long-term cognition (Colino, 2017).   
According to Colino (2017), “it is easier to protect a healthy brain than to try to repair 
damage once it is extensive” which highlights the importance of preventative measures.  Healthy 
day-to-day choices can have extremely beneficial implications for current and future patients 
(Colino, 2017).  Polyphenols and other natural compounds have also been recommended as 
dietary support due to their inherent plant-based potential to provide multi-target support at a 
biological level (Leszek et al., 2017).  These benefits include “antioxidant, anti-inflammatory 
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and antihyperglycemic activities” (Leszek et al., 2017).  Polyphenols have even shown promise 
in the interference of enzymes that have been implicated in the etiology of both AD and type 2 
diabetes including PDE and GSK-3β (Leszek et al., 2017).  While the bioavailability of many 
polyphenols has been identified as a barrier in current research, these compounds “still come 
across as promising multitarget starting points for structural optimization, namely through the 
introduction of water-soluble sugar moieties” (Leszek et al., 2017).  Research shows that 
hydrophilic factors have been implicated as natural plant-sources that may enhance bioactivity in 
vivo (Leszek et al., 2017).  The positive repercussions from simply educating patients on easy 
lifestyle changes to convalesce blood sugar and reduce insulin resistance cannot be overly 
emphasized, especially because the average life expectancy post-AD diagnosis is less than nine 
years (Chornenkyy et al., 2018).   
Recommendations 
 It has been well established that at least half of the underlying risk of developing AD has 
been associated with modifiable factors including dietary choices that lower the need for insulin 
production, and participating in moderate physical activity to reducing inflammatory pathways 
(Colino, 2017).  Research has also outlined the dramatically increased risk factor of ApoE(4) 
carriers in developing AD due to genetic abnormalities that deflect insulin signaling within the 
brain in roughly 20% of the population (Johnson, 2017).  Furthermore, as these risk factors 
accumulate, the danger of developing AD increases exponentially.  While we have been unable 
to change our genetic makeup, we have the ability to make modifiable alterations within our 
environment to control epigenetic expression and potentially make up for predetermined risk 
factors.   
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 In utilizing the term of type 3 diabetes to identify distinct pathogenic mechanisms related 
to neurodegeneration in AD, clinical medicine would be able to combat the disease accordingly 
(Steen et al., 2005).  Type 3 diabetes is a complex disorder characterized by (a) cell loss, (b) 
neurofibrillary tangles, (c) abnormal protein deposits within the brain, (d) augmented early cell 
death through abnormal signaling pathways, and (e) chronic oxidative stress, resembling, yet 
distinct from, type 2 diabetes mellitus (Steen et al., 2005).  Viewing and terming AD as type 3 
diabetes would also help induce a paradigm shift in our current reactive cycle (Steen et al., 
2005).  Cognitive deficits typically progress to full blown dementia before patients are able to 
recognize precursors that may provide lifesaving tools as therapeutic interventions in restoring 
brain function as well as possibly thwarting progression.   
Based on this review of the literature, current medical science should address AD as type 
3 diabetes and recognize the following goals and objectives:  
Clinician Education 
1.   Type 3 diabetes must be a priority on America’s national healthcare agenda. 
2.   Medical science must establish routine screening and pre-screening assessments with     
      standardized tools to uncover genetic factors, environmental risks and comorbid   
diagnoses (type 2 diabetes) that increase the risk of cognitive decline, particularly in 
susceptible populations.  
3.   High risk populations including the elderly, prediabetics, patients presenting with pro-  
      inflammatory profiles, recurrent infections, early onset cognitive decline, type 2    
     diabetes, and/or ApoE4 carriers must be identified and educated about anti-  
     inflammatory therapies. 
Early Patient Identification 
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4.  Emphasis must be placed on prediabetes education and therapeutic lifestyle changes   
     that can restore blood sugar levels (the ketogenic diet discussed in chapter 2).  
5. The utilization of cerebrospinal fluid to measure AGEs should be employed as an  
     inflammatory marker for early AD diagnosis.   
6.  Roughly 194 million people with diabetes are undiagnosed and “unaware of the long- 
     term damage” that ensues, underscoring the need for multitargeted therapies to reduce   
     the “cumulative neuropathological events that begin to take place in the earliest stages   
     of diabetes” (De Matos, De Macedo & Rauter, 2017).   
Pharmaceuticals 
7. The potential for antidiabetic agents must be examined as innovative beneficial   
     approaches in treating AD and should be considered in patient protocol. 
8. Specific prospective research must include the effects of intranasal insulin-based  
    strategies in restoring healthy brain functioning particularly in ApoE(4) carriers. 
Patient Education on Lifestyle Changes 
9.  The need for nutraceutical support like curcumin and piperine must be further  
     examined as part of adjuvant anti-inflammatory therapy, particularly for metformin   
     patients.   
10.  Efforts must be made to educate people on anti-inflammatory lifestyle choices so  
     they can make informed decisions about their own health and prevent chronic disease     
     and cognitive decline.   
11.  Mitochondrial support as a therapeutic intervention for both AD and diabetes must  
       be considered in patient protocol, particularly in halting the vicious cycle of   
       inflammation commonly exhibited in chronic diseases.   
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Biomarkers 
12.  Effective biomarkers must be established in identifying exposures to neurotoxic  
       pesticides and chemicals for the general public in order to identify sources and  
       reduce the cumulative effects of daily low-dose exposure. 
13.  Current research must continue to make strides in creating genetic screening tools for  
       use on the front lines of medicine to identify ApoE(4) carriers in order to educate  
       them on prevention strategies.   
These strategies have been recommended for current and prospective research as part of 
an action plan to support a more efficient and feasible therapeutic protocol for AD patients.  
Therefore, continuing research in these areas and implementing this proposed action plan has the 
potential to improve quality of life in AD patients while further illustrating the need to increase 
awareness of type 3 diabetes.  This would allow corresponding anti-inflammatory strategies to be 
assessed on a patient-by-patient scenario, sooner rather than later.  Going forward, a type 3 
diabetes diagnosis may provide the missing link for personalized therapy for AD patients in 
order to target multiple “pathogenic cascades in different disease stages with more efficient 
diagnostic procedures and treatment techniques with greater effectiveness and fewer side effects 
(Chen & Zhong, 2013).  It is always said in the nutrition field that the best way to treat a disease 
is to prevent it in the first place.  Increasing awareness of type 3 diabetes will no doubt shed light 
on prevention as the first line of defense while saving Americans millions of dollars in healthcare 
costs and needless pain and suffering (Levine & Goldschlag, 2015).   
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Appendix A 
Figure 1: U.S. Average Wait Time in Days 
 
 
 
Note: Adapted from Gold, J. (2014). In cities, the average doctor wait-time is 18.5 days. The  
Washington Post. Retrieved from 
https://www.washingtonpost.com/news/wonk/wp/2014/01/29/in-cities-the-average-
doctor-wait-time-is-18-5-days/?noredirect=on&utm_term=.4b073043d6a5 
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Appendix B 
Figure 2: Energy Imbalances in AD & Metformin Mechanism of Action 
 
Note. Adapted from Duran-Aniotz, C. & Hetz, C. (2016). Glucose metabolism: a sweet relief of 
Alzheimer’s disease. Current Biology, 26, R794-R815. doi: 10.1016/j.cub.2016.07.060 
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Appendix C 
Table 1: Type 2 Diabetes and AD Drug Class, Structure and Effect 
 
Note. Adapted from de Matos, A., de Macedo, M.P. & Rauter, A.P. (2017). Bridging type 2  
diabetes and Alzheimer’s disease. Medicinal Research Reviews, 38, 1,  
261-324. doi: 10.1002/med.21440 
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Appendix D 
Figure 3: Insulin Resistance through Oxidative Stress 
 
Note. Adapted from de Matos, A., de Macedo, M.P. & Rauter, A.P. (2017). Bridging type 2  
diabetes and Alzheimer’s disease. Medicinal Research Reviews, 38, 1,  
261-324. doi: 10.1002/med.21440 
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Appendix E 
Figure 4: Hyperglycemic-induced Cognitive Dysfunction 
 
 
Note. Adapted from Lee, H.J., Seo, H.I., Cha, H.Y, Yang, Y.J., Kwon, S.H & Yang, S.J. (2018).  
          Diabetes and Alzheimer’s disease: mechanisms and nutritional aspects. Clinical  
          Nutrition Research, 7, 4. 229-240. doi: 10.7762/cnr.2018.7.4.229 
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Appendix F 
Figure 5: Summary of Treatment, Prevention of T2D and AD 
 
 
Note. Adapted from de Matos, A., de Macedo, M.P. & Rauter, A.P. (2017). Bridging type 2  
diabetes and Alzheimer’s disease. Medicinal Research Reviews, 38, 1,  
261-324. doi: 10.1002/med.21440 
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Appendix G 
Figure 6: ApoE Mechanism of Action in Impaired Insulin Signaling 
 
Note. Adapted from Zhao, N., Liu, C.C., Ingelgom, A.J., Painter, M.M., Sullivan, P.M., Bu, G. et  
al. (2017). Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin 
receptor in the endosomes. Neuron, 96, 1. 115-129. doi: 10.1016/j.neuron.2017.09.003 
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Appendix H 
Figure 7: Complex Interplay of Environment, Western Disease & AD 
 
 
Note: Adapted from Stein, J., Schettler, T., Rohrer, B. & Valenti, M. (n.d.). Environmental  
factors in the Development of dementia focus on Alzheimer’s disease and cognitive 
decline. Greater Boston Physicians for Social Responsibility and Science and 
Environmental Health Network.  Retrieved from 
http://action.psr.org/site/DocServer/chap7_0926.pdf?docID=5924 
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Appendix I 
Figure 8: Inflammation, Environmental Exposure & Neurotoxic Pollutants 
 
Note: Adapted from Stein, J., Schettler, T., Rohrer, B. & Valenti, M. (n.d.). Environmental  
factors in the Development of dementia focus on Alzheimer’s disease and cognitive 
decline. Greater Boston Physicians for Social Responsibility and Science and 
Environmental Health Network.  Retrieved from 
http://action.psr.org/site/DocServer/chap7_0926.pdf?docID=5924 
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Appendix J 
Figure 9: Mitochondrial Dysfunction in AD 
 
 
Note: Adapted from Godoy, A., Leal, J.A, Zolezzi, J.M., & Braidy, N. (2014). Signaling  
pathway cross talk in Alzheimer’s disease. Cell Communication and Signaling, 12, 23.  
10.1186/1478-811X-12-23. 
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Appendix K 
Figure 10: The “Inflammation Hypothesis” of obesity-induced chronic 
inflammation and peripheral insulin resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Adapted from Chadt, A., Scherneck, S., Joost, H.G. & Al-Hasani, H. (2018). Molecular  
 links between obesity  and diabetes: “diabesity.” Retrieved from  
 https://www.ncbi.nlm.nih.gov/books/NBK279051/ 
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Appendix L 
Figure 11: The “Lipid Overflow Hypothesis” of obesity-induced ectopic lipid stores that  
cause peripheral insulin resistance and impaired β-cell function. 
 
Note: Adapted from Chadt, A., Scherneck, S., Joost, H.G. & Al-Hasani, H. (2018). Molecular  
 links between obesity  and diabetes: “diabesity.” Retrieved from  
 https://www.ncbi.nlm.nih.gov/books/NBK279051/ 
 
